Podcasts about Lancet

Trump wants $95 billion more for his Iran war while oil giants cash in — and DNI pick Jay Clayton confesses to victimizing Epstein's victims. In this episode: • Hegseth testifies war money runs dry by August 1 — demands $87 to $95 billion more on top of a nearly $1 trillion budget • Hegseth admits $37.7 billion already spent, then warns we're low on ammo on camera • US bombing hits civilian desalination systems — 10,000 Iranians without drinking water • Oil near $90 a barrel, gas near $4 — Chevron, Exxon, ConocoPhillips feast while Hormuz stays shut • Jay Clayton clears committee 9–8 for Director of National Intelligence after he spilled Epstein victims' names, addresses, and photos • Clayton won't say Biden won 2020 — and shrugs at Tulsi helping seize Fulton County ballots • Tillis and Cornyn freeze Todd Blanche's Attorney General path after Epstein survivor meeting left victims more traumatized • Cornyn holds Kari Lake and Mastriano ambassadorships hostage over PEPFAR AIDS funding — Lancet warns 14 million dead if cuts stand, one third children • Ed Martin's pardon office ignores nearly 6,000 pleas for clemency so he can free Trump donors and Clean Air Act polluters • Sunny Hostin's Harvard grad son handcuffed jogging in New Rochelle Key figures covered: Donald Trump, Pete Hegseth, Jay Clayton, Todd Blanche, Thom Tillis, Jon Cornyn, Kari Lake, Ed Martin, Kash Patel, Chelsi "Sunny" Hostin Subscribe for live shows Sunday, Tuesday, and Thursday at 6:05 PM Eastern. Recorded live on the David Feldman Show July 21, 2026 #IranWar #EpsteinFiles #ToddBlanche #PeteHegseth #Trump #JayClayton #PEPFAR #WarSupplemental #OilPrices #DavidFeldmanShow

Can an algorithm decide who sees a doctor first — and what happens when it gets the call wrong? The NHS is rolling out AI triage tools and ambient scribes across general practice, promising to shorten waiting lists and free up clinician time. In this episode of The Lancet Voice, host Niall Boyce and Chloe Wilson, senior editor at The Lancet, cast a questioning eye over the initiative. Chloe raises concerns about AI triage — including the risk of downgrading seemingly innocuous but important symptoms — and questions whether AI in health care is adding efficiency, or simply cutting costs. The hosts also examine ambient scribes in the consulting room, discussing how AI scribes may change clinical practice, or even deskill physicians. The issue isn't whether AI can help the NHS — it's whether we're asking it to do the right things, and if we are implementing it in the right way. Let us know your thoughts in the comments! The Lancet Voice is part of the Lancet Group podcast offering.  Editorial team: Niall Boyce, Miriam Sabin, Jessamy Bagenal, Richard Horton, and Gavin Cleaver Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

No episódio de hoje do Radar Médico, Juliane B. Braziliano, endocrinologista e editora médica de Endocrinologia do Portal Afya, explica a recente mudança de nomenclatura da Síndrome dos Ovários Policísticos (SOP), que passa a se chamar Síndrome Ovariana Metabólica Poliendócrina (SOMP).A atualização resulta de um consenso global publicado pelo The Lancet e busca refletir melhor o caráter multissistêmico da doença, destacando seus aspectos metabólicos, endocrinológicos, reprodutivos e psicológicos. O episódio revisa os critérios diagnósticos, os motivos para a mudança e como será a implementação da nova terminologia na prática clínica e na pesquisa. Tópicos abordados:Por que a SOP passou a se chamar SOMPCritérios diagnósticos em adultas e adolescentesManifestações metabólicas, reprodutivas e endocrinológicas da síndromeComo ocorreu o consenso global para a mudança de nomeEstratégia de implementação da nova nomenclaturaImpactos da mudança para a prática clínica, pesquisa e educação médicaDê o play e atualize sua prática clínica.

In this episode I look at the effects of climate change and also the recent hot weather from the level of the individual to the state of the planet.Links: Understanding climate change and its impacts: https://pmc.ncbi.nlm.nih.gov/articles/PMC11998295/Climate anxiety: https://mentalhealth-uk.org/news-and-insights/what-is-climate-anxiety-and-what-can-we-do-about-it/Lancet study on climate anxiety: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3918955Hope in the climate crisis: https://www.youtube.com/watch?v=XZQMVYSD9EMThirst and dehydration: https://www.nhs.uk/conditions/dehydration/Mosquitoes: https://www.cdc.gov/mosquitoes/about/where-mosquitoes-live_1.htmlClimate summits: https://www.un.org/en/climatechange/un-climate-conferencesSave your life in slow motion and those of others by subscribing now and sharing. Thank you for listening and for your support. It means a lot to me. Hosted on Acast. See acast.com/privacy for more information.

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

"Wetenschap? Dat is ook maar een mening, toch?"

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Un nouvel épisode du Pharmascope est disponible! Dans ce 180e épisode, Nicolas, Olivier, Amélie et une invitée d'expérience débutent une série de deux épisodes sur la dermatite atopique en pédiatrie. Cette première partie est consacrée à l'évaluation, au diagnostic et à la prise en charge de la dermatite atopique, ainsi que sur l'efficacité et l'innocuité des corticostéroïdes topiques.  Les objectifs pour cet épisode sont les suivants: Discuter de l'évaluation et du diagnostic de la dermatite atopique en pédiatrie. Discuter de la prise en charge de la dermatite atopique en pédiatrie. Discuter de l'efficacité des émollients dans le traitement de la dermatite atopique en pédiatrie. Discuter de l'efficacité et de l'innocuité des corticostéroïdes dans le traitement de la dermatite atopique en pédiatrie. Ressources pertinentes en lien avec l'épisode  Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020 Aug 1;396(10247):345-360. Ständer S. Atopic Dermatitis. N Engl J Med. 2021 Mar 25;384(12):1136-1143. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, et coll. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 Mar;132(3):274-312. Davis DM, et coll. Guidelines of care for the management of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2026 Apr. 3e1-26. Chu DK, et coll. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023 Dec;152(6):1493-1519. Bradshaw L, et coll. Weekly versus daily bathing for people with eczema: results of the Eczema Bathing online randomized controlled trial. Br J Dermatol. 2026 Feb 18;194(3):450-460. Santer M, et coll. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ. 2018 May 3;361:k1332. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017 Feb 6;2(2):CD012119. Ridd MJ, et coll. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child Adolesc Health. 2022 Aug;6(8):522-532. Lax SJ, et coll. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013356. Axon E, et coll. Safety of topical corticosteroids in atopic eczema: an umbrella review. BMJ Open. 2021 Jul 7;11(7):e046476 Wood Heickman LK, Davallow Ghajar L, Conaway M, Rogol AD. Evaluation of Hypothalamic-Pituitary-Adrenal Axis Suppression following Cutaneous Use of Topical Corticosteroids in Children: A Meta-Analysis. Horm Res Paediatr. 2018;89(6):389-396.

Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Substackhttps://substack.com/@theoccultrejects?r=7auau0&utm_campaign=profile&utm_medium=profile-pageCash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsAssmann, Jan. Death and Salvation in Ancient Egypt. Translated by David Lorton. Cornell University Press, 2005.Ariès, Philippe. The Hour of Our Death. Translated by Helen Weaver. Knopf, 1981.Beard, Mary, John North, and Simon Price. Religions of Rome. 2 vols. Cambridge University Press, 1998.Blackmore, Susan. Dying to Live: Near-Death Experiences. Prometheus Books, 1993.Boyce, Mary. Zoroastrians: Their Religious Beliefs and Practices. Routledge, 1979.Bremmer, Jan N. The Rise and Fall of the Afterlife: The 1995 Read-Tuckwell Lectures at the University of Bristol. Routledge, 2002.Chalmers, David J. “Facing Up to the Problem of Consciousness.” Journal of Consciousness Studies 2, no. 3 (1995): 200–219.Fenwick, Peter, and Elizabeth Fenwick. The Art of Dying: A Journey to Elsewhere. Continuum, 2008.Graf, Fritz, and Sarah Iles Johnston. Ritual Texts for the Afterlife: Orpheus and the Bacchic Gold Tablets. 2nd ed. Routledge, 2013.Greyson, Bruce. After: A Doctor Explores What Near-Death Experiences Reveal about Life and Beyond. St. Martin's Essentials, 2021.Greyson, Bruce. “The Near-Death Experience Scale: Construction, Reliability, and Validity.” Journal of Nervous and Mental Disease 171, no. 6 (1983): 369–375.Griffiths, Roland R., William A. Richards, Una McCann, and Robert Jesse. “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.” Psychopharmacology 187, no. 3 (2006): 268–283.Hornung, Erik. The Ancient Egyptian Books of the Afterlife. Translated by David Lorton. Cornell University Press, 1999.Johnston, Sarah Iles. Restless Dead: Encounters between the Living and the Dead in Ancient Greece. University of California Press, 1999.Kerr, Christopher W., et al. “End-of-Life Dreams and Visions: A Longitudinal Study of Hospice Patients' Experiences.” Journal of Palliative Medicine 17, no. 3 (2014): 296–303.Le Goff, Jacques. The Birth of Purgatory. Translated by Arthur Goldhammer. University of Chicago Press, 1984.Moody, Raymond A. Life After Life. Mockingbird Books, 1975.Nahm, Michael, Bruce Greyson, Emily Williams Kelly, and Erlendur Haraldsson. “Terminal Lucidity: A Review and a Case Collection.” Archives of Gerontology and Geriatrics 55, no. 1 (2012): 138–142.Nelson, Kevin R., Michelle Mattingly, Sherman A. Lee, and Frederick A. Schmitt. “Does the Arousal System Contribute to Near Death Experience?” Neurology 66, no. 7 (2006): 1003–1009.Obayashi, Hiroshi, ed. Death and Afterlife: Perspectives of World Religions. Greenwood Press, 1992.Osis, Karlis, and Erlendur Haraldsson. At the Hour of Death. Avon, 1977.Parnia, Sam, et al. “AWAreness during REsuscitation—II: A Multi-Center Study of Consciousness and Awareness in Cardiac Arrest.” Resuscitation 191 (2023).Plato. Phaedo. In Plato: Complete Works. Edited by John M. Cooper. Hackett, 1997.Segal, Alan F. Life After Death: A History of the Afterlife in Western Religion. Doubleday, 2004.Stevenson, Ian. Children Who Remember Previous Lives: A Question of Reincarnation. Rev. ed. McFarland, 2001.Taylor, John H., ed. Journey through the Afterlife: Ancient Egyptian Book of the Dead. Harvard University Press / British Museum Press, 2010.Tucker, Jim B. Life Before Life: A Scientific Investigation of Children's Memories of Previous Lives. St. Martin's Press, 2005.van Gennep, Arnold. The Rites of Passage. Translated by Monika B. Vizedom and Gabrielle L. Caffee. University of Chicago Press, 1960.van Lommel, Pim, Ruud van Wees, Vincent Meyers, and Ingrid Elfferich. “Near-Death Experience in Survivors of Cardiac Arrest: A Prospective Study in the Netherlands.” The Lancet 358, no. 9298 (2001): 2039–2045.Xu, Gang, et al. “Surge of Neurophysiological Coupling and Connectivity of Gamma Oscillations in the Dying Human Brain.” Proceedings of the National Academy of Sciences 120, no. 19 (2023).Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. 

We follow the footnotes on a common gyn rule, then use that same evidence-first lens to question popular fertility add-ons and persistent pregnancy myths. Along the way, we talk pretest probability, counseling tradeoffs, and why simple cutoffs often replace better clinical reasoning. • tracing the “biopsy Bartholin cysts after 40” claim back to weak citations • using pretest probability and exam features to decide on selective biopsy • weighing hysteropexy versus hysterectomy for prolapse with long-term cancer risk in mind • breaking down a Lancet review of IVF add-ons and what actually shows benefit • spotting how marketing and online forums amplify unproven fertility interventions • reviewing data on sedentary time in pregnancy and why activity restriction persists • debunking “walking progresses labor” with randomized trial evidence • clarifying early diabetes testing as screening for preexisting diabetes and when A1C makes more sense than early glucose tolerance tests Be sure to check out thinkingaboutobgyn.com for more information and be sure to follow us on Instagram.0:00 Welcome And What's Ahead0:23 Bartholin Cyst Biopsy Age Rule14:17 Prolapse Repair With Uterus Preservation21:45 IVF Add-Ons And The Lancet Review37:35 Pregnancy Activity Myths And New Data50:53 Early Diabetes Testing And A1CFollow us on Instagram @thinkingaboutobgyn.

After earning her first-class degree in chemistry from Oxford, Dorothy embarked on an impressive career in the new field of X-ray crystallography. She would ultimately earn many, many accolades for her work. Research: "Dorothy Crowfoot Hodgkin." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, Biophysical Society. “Profiles in Biophysics: Dorothy Hodgkin.” 2016. https://www.biophysics.org/profiles/dorothy-hodgkin Boon, Rachel. “Curator Rachel Boon celebrates the work of Dorothy Hodgkin.” Science Museum. 12/10/2014. https://blog.sciencemuseum.org.uk/celebrating-dorothy-hodgkin-britains-first-female-winner-of-a-nobel-science-prize/ Bragg, Sir William. “Concerning The Nature Of Things.” London. Bell & Sons. 1932. https://archive.org/details/in.ernet.dli.2015.222386/ Bud, Robert. "Discoverers and developers of penicillin (act. 1928–1950)." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-97279 Dodson, Guy. “Dorothy Mary Crowfoot Hodgkin, O.M. 12 May 1910--29 July 1994.” Biographical Memoirs of Fellows of the Royal Society , Dec., 2002, Vol. 48 (Dec., 2002). Via JSTOR. https://www.jstor.org/stable/3650256 DOROTHY CROWFOOT HODGKIN. NobelPrize.org. Nobel Prize Outreach 2026. Wed. 24 Jun 2026. https://www.nobelprize.org/stories/women-who-changed-science/dorothy-hodgkin/ Ferry, Georgina. "Dorothy Hodgkin". Encyclopedia Britannica, 8 May. 2026, https://www.britannica.com/biography/Dorothy-Hodgkin. Accessed 24 June 2026. Ferry, Georgina. "Hodgkin, Dorothy Mary Crowfoot (1910–1994), chemist and crystallographer." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-55028 Ferry, Georgina. “Dorothy Hodgkin: A Life.” Bloomsbury. 1998, 2014. Ferry, Georgina. “Dorothy Hodgkin: on proteins and patterns.” The Lancet, 384, 1496-1497. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61912-7/fulltext Ferry, Georgina. “The making of an exceptional scientist.” Nature. Vol. 464. April 29, 2010. Gamble, Jessa. “When Hodgkin met Thatcher.” Nature. Vol. 514. October 16, 2014. Hodgkin, Dorothy Crowfoot. “The X-ray analysis of complicated molecules.” Nobel Lecture, December 11, 1964. https://www.nobelprize.org/uploads/2018/06/hodgkin-lecture-1.pdf Hodgkin, Dorothy. “The Pugwash Movement.” India International Centre Quarterly. Vol. 13, No. 2. June 1986. Via JSTOR. https://www.jstor.org/stable/23001474 Howard, Judith A.K. “Dorothy Hodgkin and her contributions to biochemistry.” Nature Reviews. Vol. 4. November 2003. gale.com/apps/doc/K1631003072/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8d7c4045. Accessed 23 June 2026. Pearce, JMS. “Dorothy Crowfoot Hodgkin OM, FRS (1910-1994).” Hektoen International. https://hekint.org/2020/11/04/dorothy-crowfoot-hodgkin-om-frs-1910-1994/ Perutz, Max. “Dorothy Crowfoot ” The Independent. Via The Crystallographic Community. https://www.iucr.org/people/crystallographers/dorothy-crowfoot-hodgkin-by-m.f.-perutz Pietzsch, Jochim. “Perspectives: Enhancing X-ray vision.” Nobel Prize. https://www.nobelprize.org/prizes/chemistry/1964/perspectives/ Ramaseshan, S. “Dorothy Hodgkin and the Indian Connection.” Notes and Records of the Royal Society of London , Jan., 1996. http://www.jstor.com/stable/531845 Root-Bernstein, Robert. “Dorothy Crowfoot Hodgkin: Structure as Art.” Leonardo , 2007, Vol. 40, No. 3 (2007). Via JSTOR. https://www.jstor.org/stable/20206415 Science History Institute Museum and Library. “Dorothy Crowfoot Hodgkin.” https://www.sciencehistory.org/education/scientific-biographies/dorothy-crowfoot-hodgkin/ The Royal Society. “Dorothy Hodgkin FRS.” https://royalsociety.org/about-us/who-we-are/diversity-inclusion/case-studies/scientists-with-disabilities/dorothy-hodgkin/ “Science for peace Building cultures of cooperation and non-violence through scientific collaboration.” 2025. Via JSTOR. https://www.jstor.org/stable/resrep73183.6 University of Oxford History of Science Museum. “Modelling the Structure of Penicillin.” https://www.mhs.ox.ac.uk/backfromthedead/exhibition/the-structure-of-penicillin/index.html Vijayan, M. “An outstanding scientist and great humanist: An obituary of Dorothy Crowfoot Hodgkin.” Current Science, 10 August 1994, Vol. 67, No. 3 (10 August 1994). Via JSTOR. https://www.jstor.org/stable/24095820 Wallace, Rob. “Dorothy Crowfoot Hodgkin: Captured by Crystals.” National World War II 3/16/2022. https://www.nationalww2museum.org/war/articles/dorothy-hodgkin-penicillin-insulin See omnystudio.com/listener for privacy information.

Read the bloghttps://rawfoodmealplanner.com/how-to-naturally-boost-glp-1/Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/07-07-2026Nesta terça-feira, o boletim analisa mudanças institucionais no Reino Unido, cuidados bucais no uso de análogos hormonais e o manejo da cardiomiopatia. Abordamos a nova regra do NHS que passará a avaliar hospitais com base em indicadores de bem-estar profissional e combate à discriminação e agressões contra a equipe. Detalhamos os efeitos orais adversos ligados à semaglutida, como redução da salivação e episódios eméticos, além das condutas preventivas. Por fim, no Radar, discutimos um estudo brasileiro publicado no The Lancet mostrando que o controle de arritmias por ablação não basta para melhorar os desfechos desfavoráveis na doença de Chagas, exigindo acompanhamento multidisciplinar. Afya News. Informação médica confiável e atualizada no seu tempo.

Dorothy Hodgkin's career in X-ray crystallography impacted a lot of science in the 20th century. Part one of her story covers her early life and formative experiences that led her to her field of research. Research: "Dorothy Crowfoot Hodgkin." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, Biophysical Society. “Profiles in Biophysics: Dorothy Hodgkin.” 2016. https://www.biophysics.org/profiles/dorothy-hodgkin Boon, Rachel. “Curator Rachel Boon celebrates the work of Dorothy Hodgkin.” Science Museum. 12/10/2014. https://blog.sciencemuseum.org.uk/celebrating-dorothy-hodgkin-britains-first-female-winner-of-a-nobel-science-prize/ Bragg, Sir William. “Concerning The Nature Of Things.” London. Bell & Sons. 1932. https://archive.org/details/in.ernet.dli.2015.222386/ Bud, Robert. "Discoverers and developers of penicillin (act. 1928–1950)." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-97279 Dodson, Guy. “Dorothy Mary Crowfoot Hodgkin, O.M. 12 May 1910--29 July 1994.” Biographical Memoirs of Fellows of the Royal Society , Dec., 2002, Vol. 48 (Dec., 2002). Via JSTOR. https://www.jstor.org/stable/3650256 DOROTHY CROWFOOT HODGKIN. NobelPrize.org. Nobel Prize Outreach 2026. Wed. 24 Jun 2026. https://www.nobelprize.org/stories/women-who-changed-science/dorothy-hodgkin/ Ferry, Georgina. "Dorothy Hodgkin". Encyclopedia Britannica, 8 May. 2026, https://www.britannica.com/biography/Dorothy-Hodgkin. Accessed 24 June 2026. Ferry, Georgina. "Hodgkin, Dorothy Mary Crowfoot (1910–1994), chemist and crystallographer." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-55028 Ferry, Georgina. “Dorothy Hodgkin: A Life.” Bloomsbury. 1998, 2014. Ferry, Georgina. “Dorothy Hodgkin: on proteins and patterns.” The Lancet, 384, 1496-1497. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61912-7/fulltext Ferry, Georgina. “The making of an exceptional scientist.” Nature. Vol. 464. April 29, 2010. Gamble, Jessa. “When Hodgkin met Thatcher.” Nature. Vol. 514. October 16, 2014. Hodgkin, Dorothy Crowfoot. “The X-ray analysis of complicated molecules.” Nobel Lecture, December 11, 1964. https://www.nobelprize.org/uploads/2018/06/hodgkin-lecture-1.pdf Hodgkin, Dorothy. “The Pugwash Movement.” India International Centre Quarterly. Vol. 13, No. 2. June 1986. Via JSTOR. https://www.jstor.org/stable/23001474 Howard, Judith A.K. “Dorothy Hodgkin and her contributions to biochemistry.” Nature Reviews. Vol. 4. November 2003. gale.com/apps/doc/K1631003072/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8d7c4045. Accessed 23 June 2026. Pearce, JMS. “Dorothy Crowfoot Hodgkin OM, FRS (1910-1994).” Hektoen International. https://hekint.org/2020/11/04/dorothy-crowfoot-hodgkin-om-frs-1910-1994/ Perutz, Max. “Dorothy Crowfoot ” The Independent. Via The Crystallographic Community. https://www.iucr.org/people/crystallographers/dorothy-crowfoot-hodgkin-by-m.f.-perutz Pietzsch, Jochim. “Perspectives: Enhancing X-ray vision.” Nobel Prize. https://www.nobelprize.org/prizes/chemistry/1964/perspectives/ Ramaseshan, S. “Dorothy Hodgkin and the Indian Connection.” Notes and Records of the Royal Society of London , Jan., 1996. http://www.jstor.com/stable/531845 Root-Bernstein, Robert. “Dorothy Crowfoot Hodgkin: Structure as Art.” Leonardo , 2007, Vol. 40, No. 3 (2007). Via JSTOR. https://www.jstor.org/stable/20206415 Science History Institute Museum and Library. “Dorothy Crowfoot Hodgkin.” https://www.sciencehistory.org/education/scientific-biographies/dorothy-crowfoot-hodgkin/ The Royal Society. “Dorothy Hodgkin FRS.” https://royalsociety.org/about-us/who-we-are/diversity-inclusion/case-studies/scientists-with-disabilities/dorothy-hodgkin/ “Science for peace Building cultures of cooperation and non-violence through scientific collaboration.” 2025. Via JSTOR. https://www.jstor.org/stable/resrep73183.6 University of Oxford History of Science Museum. “Modelling the Structure of Penicillin.” https://www.mhs.ox.ac.uk/backfromthedead/exhibition/the-structure-of-penicillin/index.html Vijayan, M. “An outstanding scientist and great humanist: An obituary of Dorothy Crowfoot Hodgkin.” Current Science, 10 August 1994, Vol. 67, No. 3 (10 August 1994). Via JSTOR. https://www.jstor.org/stable/24095820 Wallace, Rob. “Dorothy Crowfoot Hodgkin: Captured by Crystals.” National World War II 3/16/2022. https://www.nationalww2museum.org/war/articles/dorothy-hodgkin-penicillin-insulin See omnystudio.com/listener for privacy information.

Weniger als vier von 100. So wenige gingen ein Jahr später noch ins Fitnessstudio. Und das lag nicht daran, dass sie nicht wollten.Fitness-Gewohnheiten – ob gesundes Essen, Supplement-Einnahme oder regelmäßiges Training – spielen neurobiologisch in einer eigenen Liga. Am Anfang arbeitet Dein Gehirn gegen Dich. Am Ende dieser Folge weißt Du, warum, und mit welchen drei Strategien Du trotzdem dranbleibst.Du erfährst:Warum sich die ersten Wochen wie ein Kampf anfühlen, und wann sich das drehtWarum die „21-Tage-Regel“ nicht funktioniert – und wie lange Du wirklich brauchst3 simple Strategien, die in Studien zu >50% häufigerem Training führen.Los geht's. Und dann: dranbleiben.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.

We've talked about eco-anxiety before on Do You Really Know, and it's real. A survey published in the Lancet in December 2021 found that 75% of young people thought the future was frightening. But others are preaching a more positive outlook, with cautious climate optimism looking set to be a trend in 2023. While our fears around the climate crisis are justified and useful, if they paralyse us out of doing anything, those feelings of hopelessness are inevitable. Psychologists call it “learned helplessness”. What cause is there for optimism? What are the arguments against climate optimism? In under 3 minutes, we answer your questions! To listen to more episodes, click here: ⁠⁠Should I walk 10000 steps a day?⁠⁠ ⁠⁠What is a vertiport?⁠⁠ ⁠⁠What is productivity paranoia?⁠⁠ A Bababam Originals podcast. Written and produced by Joseph Chance. First Broadcast: 20/1/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Can food improve brain health, memory and mood?  In this episode, Prof Felice Jacka and Prof Tim Spector explore how diet, the gut microbiome and fermented foods may affect your mood, brain function and dementia risk. Drawing on clinical trials and research involving more than 10 million people, they explain why what you eat could have a much bigger impact on your brain than most people realise, and what the latest science suggests you can do about it. Felice, who helped create the field of nutritional psychiatry, explains how food influences the brain through the gut microbiome and inflammation. She and Tim explore why some foods change brain function, which support brain health, what the evidence says about ultra-processed foods, and why diet is becoming an increasingly important part of research on brain and mental health. Learn which foods to eat more often, which foods to reduce, and simple, affordable ways to build meals that support your gut, mood and long-term brain health. From whole grains and legumes to fermented foods and everyday supermarket and grocery store choices, by the end of the episode, you'll have realistic advice that's easy to put into practice today. If the food you eat today helps shape your brain tomorrow, what small change could make the biggest difference over the next year?

Second, NBC News correspondent Ryan Nobles corners Republican Senator Roger Marshall on Meet the Press over voter fraud claims, with Hawk noting that Republicans won the House, the Senate, the presidency, and effectively control the Supreme Court in 2024, making the left-rigs-elections argument impossible to sustain. Third, an Ohio pastor from the Springfield area shares a firsthand account of what Haitian immigrants have contributed to his community, and what the TPS ruling means for families who have been there for over a decade. Hawk also covers the current conditions in Haiti that made Temporary Protected Status necessary in the first place. Fourth, Steve Schmidt and Jim Acosta discuss Megyn Kelly's racist commentary about Haitian immigrants, with Hawk responding to her record and her history with Trump going back to the 2016 debate. Fifth, Fox News broadcasts live from Trump's America 250 celebration, which is scheduled for 16 days. The footage behind the reporter shows almost no one in attendance, prompting widespread mockery including from Ron Filipkowski, Hemant Mehta, and others. SUPPORT & CONNECT WITH HAWK- Support on Patreon: https://www.patreon.com/mdg650hawk - Hawk's Merch Store: https://hawkmerchstore.com - Connect on TikTok: https://www.tiktok.com/@mdg650hawk7thacct - Connect on TikTok: https://www.tiktok.com/@hawkeyewhackamole - Connect on BlueSky: https://bsky.app/profile/mdg650hawk.bsky.social - Connect on Substack: https://mdg650hawk.substack.com - Connect on Facebook: https://www.facebook.com/hawkpodcasts - Connect on Instagram: https://www.instagram.com/mdg650hawk - Connect on Twitch: https://www.twitch.tv/mdg650hawk ALL HAWK PODCASTS INFO- Additional Content Available Here: https://www.hawkpodcasts.comhttps://www.youtube.com/@hawkpodcasts- Listen to Hawk Podcasts On Your Favorite Platform:Spotify: https://spoti.fi/3RWeJfyApple Podcasts: https://apple.co/422GDuLYouTube: https://youtube.com/@hawkpodcastsiHeartRadio: https://ihr.fm/47vVBdPPandora: https://bit.ly/48COaTB

Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9 Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0 Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026 Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7 Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

The Problem with Supplementshttps://rawfoodmealplanner.com/the-problem-with-supplements/Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

For years on True Birth and in their OB/GYN practice, Dr. Abdelhak & Kristin Mallon have made an unpopular argument: when a baby is measuring big, the safest move is usually to induce, not to wait. The conventional literature did not back them up, and plenty of academics pushed back with the same line every time, that induction does not lower the risk of a cesarean or a shoulder dystocia. In this episode they walk through two pieces of high level evidence that land squarely on their side, and they explain why this was common sense all along. They start with the bigger cultural point. We do not have natural pregnancies anymore, so it is unrealistic to expect a uniformly natural birth. Electricity, processed food, far fewer daily steps, and later maternal age all push birth weights up, which means more babies are simply too big to deliver without help. Kristin brings the midwife lens to this, including a frank look at the Ina May Gaskin farm numbers and what they actually showed. From there they get into the data, share a real shoulder dystocia save from the floor, and detour into the things that genuinely scare them in delivery, like postpartum hemorrhage, plus Dr. Abdelic's running theory that growth problems are usually about the cord, not the placenta. The take home is blunt. If your provider tells you the baby is measuring large, the right question is not whether to induce. It is when. What we cover Why "natural birth" is a moving target in a non natural world The Ina May Gaskin farm numbers and what they really tell us The landmark randomized trial on inducing large for date babies The brand new 2026 meta analysis on induction at 38 weeks How estimated fetal weight, the 90th and 95th percentiles, and hospital induction rules actually play out in practice A real time shoulder dystocia at the bedside, handled without the fanfare Why hemorrhage, not shoulder dystocia, is the emergency that worries them most "It is all about the cord," and why placental insufficiency is the wrong framing The difference between cervical insufficiency and true preterm labor How to filter real clinical advice from social media noise The research referenced The randomized controlled trial (the Lancet study): Boulvain M, Senat MV, Perrotin F, et al. Induction of labour versus expectant management for large for date fetuses: a randomised controlled trial. Lancet. 2015;385(9987):2600 to 2605. A pragmatic trial across 19 centers in France, Switzerland, and Belgium. Women with singleton fetuses above the 95th percentile were randomized to induction between 37 0/7 and 38 6/7 weeks or to expectant management. Induction significantly reduced the composite of shoulder dystocia and associated morbidity, relative risk 0.32, 95% CI 0.15 to 0.71, p equals 0.004, without raising the cesarean rate and with more spontaneous vaginal deliveries. The 2026 meta analysis (the AJOG MFM study): Paladino, et al. Induction at 38 weeks for large for gestational age or macrosomic fetuses decreases the incidence of cesarean delivery: meta analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2026. Five randomized trials, 4,083 pregnant individuals, most induced at 38 0/7 to 38 4/7 weeks for an estimated weight above the 90th percentile. Induction lowered the cesarean rate and cut macrosomia (relative risk 0.53 for 4,000 grams or more, and 0.22 for 4,500 grams or more). Shoulder dystocia and fetal fracture both trended down but did not reach significance, which is expected for outcomes this rare. Roughly 25 inductions in this window prevent one cesarean. Key takeaways A big baby is the single biggest risk factor for shoulder dystocia, and a baby does not get smaller between 38 and 40 weeks. The evidence now shows that inducing for a large for date baby reduces shoulder dystocia and cesarean delivery and increases the odds of a vaginal birth. If you are told your baby is measuring large, come prepared to ask for induction rather than waiting to be offered it. And take advice from clinicians who have actually cared for patients with your condition recently, not from a single viral story. Connect New episodes drop weekly. If you have a question or a topic you want covered, reach out, and please subscribe and leave a review wherever you listen. More at www.trubirthpodcast.com.

Dr. Amy Vertrees reflects on the weekend screening of the documentary A Thousand and One Cuts and the coaching call that followed it, unpacking why women surgeons' careers are rarely derailed by one dramatic event but by an accumulation of small, repeated moments. She backs this up with hard data: female physicians and surgeons consistently produce lower mortality and complication rates than their male counterparts across multiple large studies, including a JAMA Internal Medicine analysis of 1.5 million Medicare hospitalizations and a 2025 meta-analysis spanning 13.4 million patients — yet women retire from medicine at 49 versus 62 for men. Amy then teaches the core coaching framework from that call: the difference between a fact (something everyone would agree happened) and a thought (your interpretation of it) — including why "microaggression" is a thought, not a fact, and why that distinction actually gives you more power, not less. She closes with tactical empathy, the "mythical white male" trap, and the idea that forcing yourself to be falsely polite is its own kind of self-inflicted harm.Tsugawa Y, Jena AB, Figueroa JF, Orav EJ, Blumenthal DM, Jha AK. Comparison of Hospital Mortality and Readmission Rates for Medicare Patients Treated by Male vs Female Physicians. JAMA Intern Med. 2017;177(2):206–213. doi:10.1001/jamainternmed.2016.7875Heybati K, Chang A, Mohamud H, Satkunasivam R, Coburn N, Salles A, Tsugawa Y, Ikesu R, Saka N, Detsky AS, Ko DT, Ross H, Mamas MA, Jerath A, Wallis CJD. The association between physician sex and patient outcomes: a systematic review and meta-analysis. BMC Health Serv Res. 2025 Jan 17;25(1):93. doi: 10.1186/s12913-025-12247-1. PMID: 39819673; PMCID: PMC11740500.Saka N, Yamamoto N, Watanabe J, Wallis C, Jerath A, Someko H, Hayashi M, Kamijo K, Ariie T, Kuno T, Kato H, Mohamud H, Chang A, Satkunasivam R, Tsugawa Y. Comparison of Postoperative Outcomes Among Patients Treated by Male Versus Female Surgeons: A Systematic Review and Meta-analysis. Ann Surg. 2024 Dec 1;280(6):945-953. doi: 10.1097/SLA.0000000000006339. Epub 2024 May 10. PMID: 38726676; PMCID: PMC11542977.Wallis CJD, Jerath A, Aminoltejari K, et al. Surgeon Sex and Long-Term Postoperative Outcomes Among Patients Undergoing Common Surgeries. JAMA Surg. 2023;158(11):1185–1194. doi:10.1001/jamasurg.2023.3744Shannon G, Jansen M, Williams K, Cáceres C, Motta A, Odhiambo A, Eleveld A, Mannell J. Gender equality in science, medicine, and global health: where are we at and why does it matter? Lancet. 2019 Feb 9;393(10171):560-569. doi: 10.1016/S0140-6736(18)33135-0. PMID: 30739691. Rittenberg E, Liebman JB, Rexrode KM. Primary Care Physician Gender and Electronic Health Record Workload. J Gen Intern Med. 2022 Oct;37(13):3295-3301. doi: 10.1007/s11606-021-07298-z. Epub 2022 Jan 6. PMID: 34993875; PMCID: PMC9550938. Branford GL, Bucala MD, Hepper A, Hadeed NM, Northway RM, Brenner MJ. The Gender Gap in EHR Workload: A Comparative Analysis of Primary Care Physician In Basket Usage. J Gen Intern Med. 2025 Jul;40(10):2255-2264. doi: 10.1007/s11606-025-09629-w. Epub 2025 May 29. PMID: 40439865; PMCID: PMC12344033. Rotenstein LS, He Z, Dziura J, Tsugawa Y, Venkatesh AK, Melnick ER, Gettel CJ. Sex Differences in Physician Attrition from Clinical Practice Across Specialties: A Nationwide, Longitudinal Analysis. J Gen Intern Med. 2026 Apr 2. doi: 10.1007/s11606-026-10362-1. Epub ahead of print. PMID: 41927984.

I hear this from so many of my patients: "Dr. Shelly, I haven't changed anything—not my diet, not my exercise—but I'm gaining weight and my body just doesn't respond the way it used to." If you're a woman in your 40s or 50s, you're probably nodding right now. In this episode, I'm walking you through exactly why menopause causes weight gain, why it has nothing to do with willpower, and what breakthrough new research reveals about Foundayo—an oral GLP-1 medication—and how it helps restore the biological signals that become harder to access during this life stage.  I'm sharing real data from the 2026 American Diabetes Association Scientific Conference, including results from the ATTAIN 1 and ATTAIN 2 clinical trials that show meaningful weight loss across all menopausal stages.  But here's what matters most: the goal during menopause isn't just weight loss—it's aging healthy. You'll learn exactly what that looks like and what you need to focus on right now. Episode Highlights: What menopause actually is ( How estrogen decline drives abdominal fat storage and insulin resistance Why muscle loss and poor sleep compound weight gain How GLP-1 medications work—and what they don't do The ATTAIN trials: weight loss results before, during, and after menopause Strength training, protein intake, and the non-negotiables for sustainable results REFERENCES: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2. Presented at the 86th Scientific Sessions of the American Diabetes Association, June 2026.   Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes. Lancet. 2026.   ClinicalTrials.gov. ATTAIN-2 Trial (NCT05872620).   The Menopause Society. Menopause practice recommendations and patient resources on metabolic changes during menopause. Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Welche Nahrungsergänzung wirkt wirklich – und was ist nur teurer Urin?Am Ende dieser Folge hast Du den Überblick. Du weißt, welche 5 Supplements wissenschaftlich am besten dastehen, woran Du echte Qualität erkennst und wann Du Dir das Geld sparen kannst. Garantiert frei von Superlativen, dafür mit den Gedanken unseres medizinischen Beirats, des Sport- und Ernährungsmediziners Niels Schulz-Ruhtenberg.Du erfährst:warum dasselbe Supplement bei dem einen wie Magie wirkt und beim anderen nichts bringtwelche 5 sich lohnen (von Vitamin D bis Kreatin)was die neue COSMOS-Studie aus Harvard über Multivitamine zeigt (und warum Du sie trotzdem nüchtern einordnen solltest)wie Du sinnvolle Präparate von teurer Geldverbrennung unterscheidest

In this episode of Baby Tribe Shorts, Afif and Anne tackle the anxiety caused by recent headlines linking paracetamol use in pregnancy with autism, ADHD and intellectual disability. They walk through a major Lancet systematic review and meta-analysis, explaining why the best-quality evidence, especially sibling comparison studies, does not support a causal link between paracetamol use in pregnancy and these neurodevelopmental outcomes.The episode also explains why paracetamol remains the recommended first-line option for pain and fever in pregnancy, why untreated fever can itself be harmful, and why earlier studies may have suggested a risk because of confounding, recall bias and the reasons people take medication in the first place. The key message for parents is clear: use paracetamol when needed, at recommended doses, and don't let fear-driven headlines make pregnancy harder than it already is. https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00211-0/fulltext

In “Dharma & Empire,” Mary Thanissara and Vince Fakhoury Horn trace how the structures of Empire occupy not just land but the psyche—moving from their own Irish, Palestinian, and colonial family histories to Gaza, climate, and class—and ask what a more revolutionary Dharma might require of practitioners right now.

Retracted articles hit a high of 10,000 in 2023, representing an increase of almost ten times in ten years. The introduction of AI brings incredible benefits to science, but could also add to the seemingly endless tide of papers that are fraudulent, misleading, or just plain wrong. What can journals such as The Lancet do to rise to this challenge, keeping the scientific record accurate, honest, and transparent? Editors Niall Boyce and Sabine Kleinert are joined by Professor Lex Bouter from Vrije Universiteit Amsterdam, and Professor Mai Har Sham of the Chinese University of Hong Kong to discuss a new Lancet Commission. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01528-4/fulltext The Lancet Voice is part of the Lancet Group podcast offering.  Editorial team: Niall Boyce, Miriam Sabin, Jessamy Bagenal, Richard Horton, and Gavin Cleaver Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Warum profitieren die Aktienkurse der Hyperscaler aktuell nicht vom KI-Boom? OpenAI baut zusammen mit Broadcom seinen ersten eigenen Inferenz-Chip und verschiebt den geplanten IPO. Claude wächst 75 Prozent bei zahlenden Consumern. Die Trump-Administration verlangt einen gestaffelten Release von GPT 5.6. Google verliert mit Adler und Pritzel zwei weitere Schlüssel-Forscher an Anthropic. Lancet meldet: KI-Halluzinationen haben falsche Zitate in wissenschaftlichen Papers versechszehnfacht. Azeem Azhar legt mit "State of the AI Economy" Zahlen zur $175 Mrd. AI-Runrate vor. Bloomberg rechnet vor, dass KI-Umsätze die Data-Center-Abschreibungen jetzt bereits decken. Meta launcht Brillen mit Kylie-Jenner-Edition und plant eine Prediction-Markt-App namens Arena. Kalshi raised auf $40 Mrd. Bewertung. Die Washington Post testet KI-Chatbots auf politischen Bias. Waymo Germany GmbH ist in München registriert, Finn wird Unicorn und Taktile holt Goldman Sachs als Lead-Investor.  Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Hyperscaler-Selloff (00:15:32) OpenAI baut Inferenz-Chip mit Broadcom (00:19:41) Siri als Deep-Seek-Moment für OpenAI? (00:22:23) OpenAI verschiebt IPO auf 2027 (00:24:57) Claude wächst 75% bei zahlenden Consumern (00:29:38) Trump-Admin staffert GPT 5.6-Release (00:32:41) Fable-5-Wette: Prediction-Markt-Insider? (00:34:39) Google verliert Adler & Pritzel an Anthropic (00:37:52) Lancet: KI-Halluzinationen in Wissenschaft (00:39:50) Azeem Azhar: $175 Mrd. AI-Runrate (00:43:09) AI deckt jetzt schon Data-Center-Abschreibungen (00:47:15) Meta-Brillen mit Kylie-Jenner-Edition (00:49:19) Meta plant Prediction-Markt-App Arena (00:56:45) Kalshi raised auf $40 Mrd. Bewertung (00:58:05) Zhipu plant zweite HK-Aktien-Tranche (00:58:58) Cerebras Q1: Umsatz fast verdoppelt, Aktie -10% (01:00:03) Washington Post: KI-Chatbots links-biased (01:04:46) Waymo Germany GmbH in München registriert (01:08:35) Finn wird Unicorn mit €140 Mio. Series D (01:11:23) Taktile raised $110 Mio. von Goldman Sachs Shownotes OpenAI und Broadcom enthuellen Custom-Chip Jalapeno - reuters.com NYT: OpenAI verschiebt IPO auf 2027, $1 Bio. als Ziel - nytimes.com Trump-Admin verlangt staged Release von GPT 5.6 - theinformation.com Claudes Zahlende-Consumer-Basis waechst 75% in 2026 - techcrunch.com Google verliert Adler & Pritzel an Anthropic - bloomberg.com Lancet: KI-Halluzinationen multiplizieren falsche Zitate in Papers - thelancet.com Azeem Azhar: State of the AI Economy - xcancel.com Bloomberg: KI-Nachfrage rechtfertigt Data-Center-Buildout-Kosten - bloomberg.com Meta-Brillen Adventurer, Fury & Kylie Starfire - bloomberg.com NYT: Meta entwickelt Prediction-Markt-App "Arena" - nytimes.com Kalshi raised auf $40 Mrd. Bewertung - ft.com Zhipu plant Multi-Mrd.-Share-Sale in Hongkong - bloomberg.com Washington Post testet KI-Chatbots auf politischen Bias - washingtonpost.com FAZ: Waymo Germany GmbH in Muenchen registriert - faz.net Finn wird Unicorn mit €140 Mio. Series D - techfundingnews.com Taktile raised $110 Mio. von Goldman Sachs & Tiger - fortune.com Handelsblatt: VC Judith Dada wird Co-CEO bei Langdock - handelsblatt.com ARD-Doku "Die Wahrheit ueber Google" (nicht gesendet) - ardmediathek.de

“I may be the expert in cancer, but you are the expert in you.”—Elisa Port, MDGround Truths is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Dr. Elisa Port is Professor of Surgery, Icahn School of Medicine at Mount Sinai; Chief of Breast Surgery for the Mount Sinai Health System; Director of the Dubin Breast Center; and Director of the Center of Excellence for Breast Cancer at the Mount Sinai Tisch Cancer Center, a NCI-Designated Comprehensive Cancer Center. She is remarkably well qualified to provide guidance for prevention and treatment of breast cancer, and runs a model program at Mount Sinai in New York (←we'll get into why I say that).She has just published a terrific book that centers around the concept of informed optimism. Many of her patient stories are integrated.We tried to cover the waterfront during our conversation including:—4 Ws for reduction of risk: weight, walking, wine, and working out (especially in Nature, “green exercise”)—Only 10-12% of women will ever develop breast cancer during their lives —Role of adipocytes (fat cells), aka estrogen and inflammation factories—Misinformation (underlying the need for this book)—Pervasive myths of magic supplements, with safety issues of unregulated intravenous drips and others when analyzed turned out to be crushed up, dried house plants—Total body MRI: mixed results from her patients —Breast cancer on the rise in young women. Dr. Port relates about recent patients diagnosed in their 20s. Some without BRCA or other pathogenic mutation. Why?—Mammograms in non-dense breasts pick up 80-90% of breast cancer. It's the 40-50% women with dense breasts, which the scan is trying to find a polar bear in a snowstorm, is a problem. The problem with false-positives.—Use of AI with mammography for increased initial detection, prevention, detect high-risk in women with a “normal” mammogram, and risk of heart disease (see my recent Ground Truths and piece in The Lancet on this important topic)—Mount Sinai provides Transpara AI (the one validated by the big Sweden trial of >100,000 women) to all women getting mammograms FOR FREE. That is the best validated AI tool in medicine today!—How a mammogram saved a patient's life, not about breast cancer!—Hormone replacement and birth control pills. How to assess benefit and risk in women young and older? Differences in the hormone risks.—Tamoxifen for primary prevention in high-risk people. Reduction of breast cancer in 50% or more in these women. In some subgroups reduction as high as 80%!—GLP-1 drugs may reduce breast cancer risk and this may not just be related to weight loss—Lack of utilization of Genetic testing (it could be your father). I disagreed with respect to use of polygenic risk scores, as I wrote about in SUPER AGERS—“I just wanted to scream out on top of the mountain about genetic testing, family history, and early screening.” Tennis legend Chris Evert—The lack of our ability to assess the immune system in the clinic and how that could change the face of prevention and very early detection of breast cancerAn infographic summary I made on Dr. Port's book with the help of NotebookLM****************************************Thank you YOUR DOCTOR KLOVER, Diane Romero, Bob Fleischman, Danielle, MagnaAnimus, and 450+ others for tuning into my live video with Elisa Port! Join me for my next live video in the app.A big thanks to all the Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you're not a subscriber, please join!If you found this interesting PLEASE share it!Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 51 summer interns coming in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn't do this expanded program without the funds coming in through Ground Truths. Get full access to Ground Truths at erictopol.substack.com/subscribe

In part two of this two-part series, Mike and Ryan discuss why families often abandon medication too quickly after a single difficult trial, the importance of trial-and-error in finding the right medication regimen, and why genetic testing isn't the shortcut many parents hope it will be.Find Mike @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.grownowadhd.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Ryan @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.adhddude.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Timestamps[00:00:00] Start[00:00:46] Why Families Give Up on Medication Too Easily[00:01:30] Two Main Stimulant Categories Explained[00:03:42] Non-Stimulant Medication Options[00:04:22] Why Medication Alone Is Not Enough[00:07:15] Genetic Testing Is Not Recommended[00:09:43] Key Takeaways on ADHD Medication[00:12:13] Final Thoughts on Kids and Medical DecisionsCitationsAmerican Academy of Child and Adolescent Psychiatry. (2020). Clinical use of pharmacogenetic tests in prescribing psychotropic medications for children and adolescents. ⁠https://www.aacap.org/aacap/Policy_Statements/2020/Clinical-Use-Pharmacogenetic-Tests-Prescribing-Psychotropic-Medications-for-Children-Adolescents.aspx⁠American Academy of Child and Adolescent Psychiatry. (2022). Attention-deficit/hyperactivity disorder: Parents' medication guide. ⁠https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/ADHD_Medication_Guide-web.pdf⁠American Psychiatric Association. (n.d.). What is ADHD? ⁠https://www.psychiatry.org/patients-families/adhd/what-is-adhd⁠Centers for Disease Control and Prevention. (2024). Clinical care of ADHD. ⁠https://www.cdc.gov/adhd/hcp/treatment-recommendations/index.html⁠Dalsgaard, S., Leckman, J. F., Mortensen, P. B., Nielsen, H. S., & Simonsen, M. (2015). Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: A prospective cohort study. The Lancet Psychiatry, 2(8), 702–709. https://doi.org/10.1016/S2215-0366(15)00271-0Dalsgaard, S., Østergaard, S. D., Leckman, J. F., Mortensen, P. B., & Pedersen, M. G. (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. The Lancet, 385(9983), 2190–2196. https://doi.org/10.1016/S0140-6736(14)61684-6de Vries, W., Boer, M., Stevens, G. W. J. M., & van Dorsselaer, S. (2025). Exploring concept creep: Youth's portrayal of ADHD on TikTok. SSM Mental Health, 7, 100374.Harpin, V., Mazzone, L., Raynaud, J. P., Kahle, J., & Hodgkins, P. (2016). Long-term outcomes of ADHD: A systematic review of self-esteem and social function. Journal of Attention Disorders, 20(4), 295–305. https://doi.org/10.1177/1087054713486516Myer, N. M., Boland, J. R., & Faraone, S. V. (2018). Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Molecular Psychiatry, 23, 1929–1936.Shaw, M., Hodgkins, P., Caci, H., Young, S., Kahle, J., Woods, A. G., & Arnold, L. E. (2012). A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: Effects of treatment and non-treatment. BMC Medicine, 10, 99. ⁠https://doi.org/10.1186/1741-7015-10-99⁠Wetterer, L. (2020). Attention-deficit/hyperactivity disorder: AAP updates guideline for diagnosis and management. American Family Physician, 102(1), 58–60.Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. ⁠https://doi.org/10.1542/peds.2019-2528⁠Yeung, A., Ng, E., & Abi-Jaoude, E. (2022). TikTok and attention-deficit/hyperactivity disorder: A cross-sectional study of social media content quality. The Canadian Journal of Psychiatry, 67(12), 899–906. ⁠https://doi.org/10.1177/07067437221082854⁠

This show has been flagged as Clean by the host. -------------------- 01 Introduction This is the second follow up to my 8 part series on nuclear power. In this episode I will attempt to answer a question posed by brian in ohio in a comment on HPR4583. In that comment he said: 02 -------------------- Loving this series. Maybe Whiskey Jack could give some cost comparisons between large and small reactors. He could also give us a realistic look at nuclear plant safety/accidents compared to conventional power production. Looking forward to the episode on FORTH generation reactors ;-) -------------------- 03 End of quote. The first question I answered in my previous follow up, which was HPR4628. In this episode I will attempt to answer the second question, which was about the safety of nuclear power compared to other sources of electrical power generation. One of the HPR janitors encouraged me to make this episode, so I think we can thank him for getting another HPR episode made. 04 Defining the Scope First, let's define the scope of the question. This will cover electrical power generation only. Within that scope I will consider only the following sources of energy. 05 Coal Oil Natural Gas Hydroelectric Nuclear Wind Solar I won't cover geothermal, wave, or tidal power as these are only used in very small amounts and so there simply isn't enough literature on them to base a discussion on . 06 Foreshadow Conclusion I should mention right away that I cannot provide absolute answers to this question in the form of a nice, neat ranking table based on numbers from peer reviewed scientific sources. The reasons for this will become apparent, but to put it briefly, the data on which to base such a ranking simply doesn't exist. I will however provide context within which people can think about the issue. Wherever possible, I will provide links to the references that I used in the show notes so you can read further on this yourself. -------------------- 07 Energy Catastrophism versus Energy Uniformitarianism First though I need to go off on a slight geological detour in order to explain an important analogy that I will use. 08 In the 19th century there was a great debate among geologists over what is known as catastrophism versus uniformitarianism. In seeking to explain the origins of the earth and of the landscape that we see around us, there were two points of view. 09 One was "catastrophism". This is the belief that the mountains, valleys, and plains that we see around us were formed as a result of great catastrophes which occurred relatively recently in earth's history. This explanation was necessary in order to fit geological features into an earth that was believed to be only a few thousands of years old. This view was heavily influenced by religious belief. In this view Noah's flood was the great catastrophe and the fossils of dinosaurs were the remains of animals who had not been saved on the ark and so had died in the flood. 10 The other point of view was uniformitarianism. This was the hypothesis that the landscape we see around us can be explained by the very slow accumulation of very small changes over very long periods of time. For this to be true however, the earth had to be far older than the few thousand years that a literal reading of the bible would suggest. The earth in fact had to be many, many, millions of years old. 11 Eventually, the uniformitarian view won out and people understood that while some catastrophes can take place, the shape of the landscape is overwhelmingly due to small changes over very long periods of time. 12 How is this Relevant to this Episode You Ask? How this is relevant is that I will use this analogy to explain how we need to think about energy and safety. Very small numbers of deaths and injuries multiplied over many occurrences can add up to big numbers, comparable in scale or possibly even larger than a single catastrophe or even several of them. 13 I don't know if anyone else has used this analogy before, I have just thought of this when writing the script for this podcast. None the less, I think it is a very useful way of helping to understand the issues. 14 As an example of this, think about the well known case of the safety of flying versus the safety of travelling in your car. Air crashes are catastrophes that make the headlines. Automobile crashes are seldom more than local news at best. You have probably heard many times the claim that if you making a trip somewhere, you are safer to fly than to drive yourself in your car. 15 Example - Hydro versus Solar I will now present an example of this. Hydro electric power has some notable large scale catastrophes associated with it. Roof top solar power does not have any notable catastrophes that I am aware of. However, which is safer? 16 Hydro Catastrophes Here are three examples of hydro electric catastrophes in just one country, Italy. The Vajont Dam which collapsed in1963 An estimated 1,917 to 2,500 people died. The Sella Zerbino dam which collapsed in 1935. More than 100 people died. The Gleno Dam which collapsed in 1923. An estimated 350 people died. https://damfailures.org/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4997708/ 17 I haven't tried to compile a global list of the worst hydro electric dam collapses, as this sort of information is actually very difficult to find, even on web sites dedicated to dam failures. An additional problem is that information on whether a dam was used for electric power generation or not is often not available. 18 Dam failures where contradictory or insufficient information is available on whether there was an associated hydro power plant include the 1975 Banqian Dam failure, where death estimates range up to a quarter of a million. 19 Solar Panel Slow Accumulation Contrast this with roof top solar panels. Many small accidents can add up to big numbers as well. 20 Health and safety literature discussing solar panel safety mention things such as Falls from roofs. Electric shock. Arc flash (burns from electrical arcing). Normal electrical safety procedures which are based around locking out sources of energy do not work with solar panels which makes safety more difficult. Heat stress due to working exposed in the hot sun. Warning from US government on falls by solar panel installers. https://stacks.cdc.gov/view/cdc/228946 https://www.osha.gov/green-jobs/solar 21 Why We Cannot Compare the Two Hydro catastrophes are not well documented, but we can at least find records of some of the most notable ones. However, even those have very large variations in estimates of deaths. 22 Roof top solar deaths however are largely undocumented. The industry is largely unregulated. There is no central authority which accumulates many individual deaths or injuries. At best there are worker and public safety bodies who simply accumulate those statistics into general construction or household injuries. 23 Thus we have no reliable means of comparing the two energy sources on a comparable basis. We face the same problem with all other major electrical energy sources. So far as I am aware, there are no peer reviewed scientific studies which compare the relative safety of all of the major electrical energy sources we are considering here based on actual numbers. -------------------- 24 Safety Risks I will now try to list some the major hazards for each of energy sources we are considering. There is however limited data available. In many cases we just have reference to worker safety organizations as to what the hazards are. I will not attempt here to put numbers to these here. Categories 25 Coal, Oil, Natural Gas The hazards are Air pollution Mining and oil field accidents Pipeline explosions Transportation accidents. These- move a lot of material so these are significant. 26 Hydroelectric These include Dam collapse Drowning 27 Nuclear These include Radiation exposure 28 Wind These include Falls Confined space deaths (there is not much detail on this) Electric shock Ice throws (that is, throwing pieces of ice off the blades) This technology has a significant problem with people working alone which greatly increases risks associated with other dangers. 29 Solar These include Falls Electric shock Arc flash Heat stress 30 I have not tried to cover all possible risks associated with each category, just the ones which each industry considers to be the risks they concern themselves with. There does not exist any means by which risks of similar types are compared across different industries. 31 Reliability of Supply is Also Safety In a completely electrified net zero society, reliability of supply is a safety matter. People will die in very large numbers in cold climates if they do not have heat. If we have no fossil fuels, we need to also consider how reliably does a grid based on any of the options work. I have not seen anyone attempt to address this question and will not attempt to address it here. However, it must be addressed in any comprehensive attempt to rank safety. -------------------- 32 Studies or Articles on Estimates of Relative Safety Despite the difficulties of comparing the safety of different sources of energy, some people have attempted this anyway. Different estimates done at different times had different focuses, so unfortunately we do not have a nice set of studies that we can neatly use to cross check one another. I will however list the names and the authors and summarize the results. -------------------- 33 The Health Hazards of Not Going Nuclear By Dr. Petr Beckman Published in 1976 The author of this book tried to address the relative safety of different sources of energy in the mid 1970s. However, it is old at this point, so I won't bother digging through its pages to find his figures. 34 He mainly focused on comparing electric power generated with coal to nuclear. His conclusion was that if the goal was to prevent deaths or ill health in the process of generating electricity, then the logical conclusion was to replace coal fired power plants with nuclear. 35 The book was relatively well known at the time, as least as far as books on energy are concerned, so I thought it was still worth mentioning. I happen to have a copy of this book which I bought back in that time period It was the 8th printing of the book, so it would appear to have had relatively good sales. 36 The author did address the issue of what I have termed "catastrophism" in his comparison of different energy sources, although I don't know if he used this phrase. I don't know if he was the first to use this sort of analysis, but he certainly was very influential in terms of popularizing it. -------------------- 37 Risk of Energy Production by Herbert Inhaber Publication AECB 1119 March 1978 This study is a scientific paper from the same time period as the book "The Health Hazards of Not Going Nuclear". 38 He based his risk estimates largely on estimates of the amount of material which was used in the construction and operation of various power sources. While we could argue over whether or not this is a valid methodology, I think any such argument would be pointless as I think the age of the study alone renders it not relevant today anyway. Advancements in materials have changed the basis results significantly by now. However, as it exists I thought I would mention it to show that the idea of comparing energy sources to each other is not a new one. The author compared a wider variety of potential sources than Beckman did. 39 Here's his conclusions. He assumes equal amounts of energy produced by each method. The numbers are normalized such that the total sums to 100%. You can think of it in terms of what proportion of total deaths or injuries would result from each source if each were equally used. 40 Coal 27.5% Oil 25.6% Methanol 16.7% Wind 10.8% Solar photovoltaic 9.2% Thermal 8.1% Solar space heating 1.5% Ocean thermal 0.4% Nuclear 0.13% Natural Gas 0.08% 41 His natural gas estimate is drastically different from that of other authors. I am not going to worry about explaining it however, as the study is as I said old enough to be not very relevant anyway. I am mainly including this here out of historical interest. 42 As a footnote, the methanol he refers to would be synthesized from wood. This was a popular idea in that era as a means of providing liquid fuels for transportation. Practical battery electric cars in those days were strictly science fiction. 43 The ocean thermal category is a real blast from the past and I had forgotten all about that concept. It was a very popular idea at that time and was supposed to be *the* big and upcoming thing in renewable energy. It involved various means of attempting to extract energy from differences in water temperature at different depths in the ocean. It gradually faded away however, as despite great efforts being put into it, designs never proved to be practical. -------------------- 44 Electricity generation and health Anil Markandya, Paul Wilkinson Published in the Lancet, Vol 370, 15 September 2007 45 This is more recent than the previous one, although it is nearly 20 years old at this point. Unfortunately it doesn't cover wind or solar, just fossil fuels and nuclear. However it is still useful, and the Lancet is a very reputable peer reviewed journal. 46 I will present just the results rather than discussing the whole paper. The authors break it down into deaths among the public, occupational deaths, and air pollution related deaths, serious illness, and minor illness. 47 They break the energy sources down into lignite, coal, gas, oil, biomass, and nuclear. Lignite is a type of very low grade coal used mainly for electric power generation. In this paper biomass refers to energy crops and forest residues. 48 I will summarize the results by category rather than trying to describe a table that has 6 rows and 5 columns. All numbers are normalized in terms of deaths or cases per TWh. 49 Occupational deaths from accidents lignite 0.1 coal 0.1 gas 0.001 oil no data biomass - no data Nuclear is 0.019. 50 Deaths among the public from accidents lignite 0.02 coal 0.02 gas 0.02 oil 0.03 biomass no data Nuclear 0.003 51 Air pollution deaths lignite 32.6 coal 24.5 gas 2.8 oil 18.4 biomass 4.63 Nuclear 0.052 52 Air pollution serious illnesses lignite 298 coal 225 gas 30 oil 161 biomass 43 Nuclear 0.22 53 Air pollution minor illnesses lignite 17,676 coal 13,288 gas 703 oil 9,551 biomass 2,276 Nuclear no data 54 Natural gas edges out nuclear power slightly in terms of occupational safety, but in every other category nuclear is drastically lower in terms of ill effects than any of the alternatives. -------------------- 55 2020 Fatalities for US Roofers Increased 15% as Solar Roof Installations Increase Published in The Next Big Future July 6, 2021 by Brian Wang 56 This seems to be written by someone who has a popular science blog. I'm not familiar with it personally, but he addresses the subject so I'll list it. The title implies that it's all about rooftop solar, but he provides comparative numbers for the other energy sources of interest, so that is useful for our purposes. However, he doesn't describe his methodology, so we need to treat them with some caution. Here are his results These are deaths per thousand terawatt hours. 57 Coal - 100,000 Oil - 36,000 Natural gas - 4,000 Hydro - 1,400 Rooftop solar - 440 Wind - 150 Nuclear - 90 58 If we plot these numbers on a bar chart, coal and oil are so large that all of the others are squished to the bottom of the chart and are difficult to see at all. Let's therefore look at these in terms of orders of magnitude. Keep in mind that this is a logarithmic scale. This means that the difference between 4 and 5 is much greater in linear terms than the difference between 1 and 2. 59 Coal - 5 Oil - 4 Natural gas - 3 Hydro - 3 Rooftop solar - 2 Wind - 2 Nuclear - 1 60 Each of these numbers represents an order of magnitude, that is a power of ten. We can see that with rooftop solar, wind, and nuclear, the numbers are so close and the uncertainties are so great and their relative values so small compared to say coal that they can be seen as equivalent so far as safety is concerned. -------------------- 61 What are the safest and cleanest sources of energy? by Hannah Ritchie Published in Our World in Data First published in 2017, updated in 2022 and 2024 62 The author of this study addressed both deaths and greenhouse gas emissions. Deaths from accidents and air pollution are normalized to per TWh of electricity, while greenhouse gas emissions are normalized to GWh of electricity over the life cycle of the plant. 63 Here are the death figures. Coal 24.6 Oil 18.4 Biomass 4.6 Natural Gas 2.8 Hydro power 1.3 Wind 0.04 Nuclear 0.03 Solar 0.02 64 For greenhouse gas emissions the figures are Coal 970 tons Oil 720 tons Natural gas 440 tons Biomass 78 to 230 tons Solar 53 tons Hydro power 24 tons Wind 11 tons Nuclear 6 tons 65 If we take the death figures and rank them by order of magnitude as we did with the previous article, we get the following. 66 Coal - 4 Oil - 4 Biomass - 3 Natural Gas - 3 Hydro power - 3 Wind - 1 Nuclear - 1 Solar - 1 67 Keep in mind that the previous article covered only rooftop solar and not large industrial installations, and so is not directly comparable. Also the units are different, with the previous article being in terms of thousand TWh, and this one being in TWh. If we exclude solar (as the numbers are not comparable), Brian Wang's numbers are between 1.5 to 4 times higher than Ritchie's, except for hydro which are almost identical. I think this latter is due to both sets of numbers are dominated by one exceptionally big hydro accident. 68 Overall however, the relative rankings are quite comparable. Ritchie's numbers for deaths from coal, oil, and natural gas appear to be directly from the study by Markandya and Wilkinson mentioned above. For the benefit of those who are wondering, Ritchie specifically states that her numbers for nuclear include the Chernobyl and Fukushima accidents. -------------------- https://www.iaea.org/publications/magazines/bulletin/21-1/solar-power-more-dangerous-nuclear Direct link to file https://www.iaea.org/sites/default/files/publications/magazines/bulletin/bull21-1/21104091117.pdf https://ourworldindata.org/safest-sources-of-energy https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61253-7/abstract https://www.nextbigfuture.com/2021/07/2020-fatalities-for-us-roofers-increased-15-as-solar-roof-installations-increase.html -------------------- 69 Conclusion from Studies Remember that in engineering terms, when comparing groups of numbers which contain both both very small numbers and one or more very large numbers, the differences between the small numbers are often not significant. The differences between the small numbers may be the product of our ability to measure these things rather than any real differences. 70 For example, in the article by Ritchie wind power would appear to be twice as dangerous as nuclear. However, the difference between them is 0.02 compared to 24.6 for coal. In other words, the difference between apparently "dangerous" wind and apparently "safe" nuclear is equivalent to 0.08% of the total for coal. It's therefore meaningless and a red herring to even worry about. 71 With the above taken into consideration, generally the different sources of energy fall into two broad categories in terms of number of deaths, injuries, and illnesses. The fossil fuels and biomass fall into one group and wind, solar, and nuclear into another group. 72 Hydro power would seem to fall into the higher risk category or at least somewhere between the two, but this I suspect is mainly due to one exceptionally large dam collapse in China, the Banqian Dam failure in 1975. This is mentioned as being specifically included in the article written by Ritchie. This was a multi-purpose dam, and information on this dam is difficult to find. It is not clear to me whether it had a hydro electric generator associated with either it or another dam that was part of the same system. 73 Some people therefor may argue for its exclusion from the numbers. Of course some people may argue for its inclusion anyway, as it was a dam regardless of whether it actually had an electric generator attached. If we exclude it, then I think the numbers for hydro power would fall into the same range as for nuclear, wind, and solar. 74 Most people would consider hydro power to be safe and clean enough regardless of this and I will rank it as such in any conclusions that I come to. As you can see, even if we have numbers, it can be a matter of opinion as to how to interpret them. -------------------- -------------------- 75 Taking a Systems Approach Now let's take a look at the broader energy picture today and into the future. Many countries in many parts of the world have committed to the concept of "Net Zero", which means eliminating carbon emissions on a net basis. Net zero essentially means the complete electrification of society. We must therefore have electrical energy on demand and at low cost. We must as a result of this look at complete electrical systems rather than individual sources in isolation. 76 At one time many electrical systems were entirely coal or entirely hydroelectric. This is no longer the case. There are now major amounts of wind and solar involved in many countries. However these are inherently intermittent. This means that other sources of energy are inherently also required to have a functional system. 77 If any particular solution inherently requires fossil fuels to meet part of the demand, then the safety, pollution, and climate issues relating to those fossil fuels have to be factored in to that complete system when trying to come up with a relative ranking. Talking about Individual sources in isolation are therefore meaningless in these countries. 78 There are battery systems, but these are mainly used to stabilize and regulate the grid plus to a lesser degree to smooth out short term daily peaks in demand. They do not have the ability to store large amounts of electricity on a large scale for an entire grid for days, weeks, and months to make up for intermittency. 79 So a serious attempt to rank sources of energy would need to look at a variety of representative countries and for each one come up with a plan that involves 'x' megawatts from source 'a', 'y' megawatts from source 'b', etc., and total up the values for each. 80 I am not aware of anyone who has studied this larger issue. However, the problem has to be addressed from this perspective in order for any answer to be useful. Not taking this into account is like ordering a diet soft drink to go with with a high calorie meal and assuring yourself that your plans to diet are fine. 81 This is not to imply there is anything inherently wrong with wind or solar. It does mean that if your goal is to achieve both net zero and a clean environment, you have to look at your entire energy system as a complete system rather than focusing on what you feel are the most reassuring parts of it while ignoring the rest. This does however add to the argument that it is in fact inherently very difficult to come up with a system of ranking energy sources for safety. -------------------- 82 Nuclear, Climate, and Clean Air - Contrasting Examples To give a tangible example we will now look at two different places that followed two divergent paths at roughly around the same time frame. These are the province of Ontario in Canada, and Germany. 83 Ontario had a mix of coal, hydro electric, and nuclear generating plants. Germany had a mix of coal, nuclear and natural gas plants. Ontario shut down their coal fired plants and kept their nuclear plants. Germany however shut down their nuclear plants and kept their coal fired plants. 84 The Phase Out of Coal in Ontario In 2003 Ontario decided to close all of its coal fired generating plants, which consisted of 19 units (that is boilers and turbines) totalling 8,800 MW. This phase out was completed by 2014. 85 Here are the figures for amount of power generated by each energy source in 2003 and 2014. Nuclear went from 42% to 60% Hydro went from 23% to 24% Gas went from 11% to 9% Coal went from 25% to 0% Non-hydro renewable went from 0% to 7%. 86 As you can see, the bulk of that replacement came from increased use of nuclear power. Furthermore, this did not result in simply replacing coal with natural gas. While gas is cleaner than coal, it still has emissions and if you recall from the studies that we looked at earlier, had an estimated death rate roughly 2 orders of magnitude greater than nuclear, solar, or wind. 87 To put this in more practical terms, at one time Toronto regularly had clouds of smog obscuring it, to a large extent due to these coal fired power plants With the phase out of coal, smog days went to zero in 2015 compared to 53 a decade earlier. The 2023 figures for Ontario show carbon emissions of 53 grams per kWh of electricity generated. We can use this as a rough benchmark comparison for total emissions. 88 The Phase out of Nuclear in Germany Until March of 2011, Germany generated one quarter of its electrical power from nuclear. Starting in 2011 however, they began shutting down their nuclear power plants. These were then phased out over the next decade. However, the coal plants were to be kept to 2038. In 2026 Germany began talking about increasing use of coal in order to save gas. In the same year the German chancellor Friedrich Merz stated that the phase out of nuclear was a quote “serious strategic mistake”. EU Commission President Ursula von der Leyen said it was "a strategic mistake for Europe to turn its back on a reliable, affordable source of low-emissions power". 89 I won't go into the details of the phase out, but let's look at some emissions numbers for Germany. If we look at the official numbers from the European Environmental Agency for 2024, for Germany their emissions were 298 grams per kWh of electricity generated. Recall that we are using emissions as a very rough guide to amount of air pollution, and that this has a direct effect on the safety of the overall electrical energy system. 90 So, who actually made their people safer, Ontario who phased out their coal plants and kept their nuclear plants, or Germany who phased out their nuclear plants and kept their coal plants? 91 If you want a comparison directly within Europe, then Germany has one of the highest rates of emissions per kWh of electricity generated, whereas France, who use mainly nuclear power, have one of the lowest at 43 grams per kWh of electricity generated. Again, who is making their people safer, Germany or France? 92 I don't want to make it sound like I am picking on Germany. I am also not going to tell them how they ought to run their country. However they provide a good real world example of how we need to look at things in overall context when we are thinking about the choices that we make. https://www.ontario.ca/page/end-coal https://www.cbc.ca/news/canada/windsor/smog-study-shows-significant-decreases-in-pollutants-in-ontario-1.4151183 https://www.eea.europa.eu/en/analysis/indicators/greenhouse-gas-emission-intensity-of-1 https://world-nuclear.org/information-library/country-profiles/countries-g-n/germany https://www.politico.eu/article/friedrich-merz-is-right-to-reject-germanys-nuclear-phase-out-says-iea-chief-fatih-birol/ https://www.politico.eu/article/germany-considers-ramping-up-coal-power-to-avert-energy-crisis/ https://www.iea.org/countries/estonia/electricity https://www.iea.org/countries/malta/electricity -------------------- 93 Conclusions As we can see, there don't appear to be an abundance of peer reviewed scientific studies that we can simply point to in order to answer the question of safety of all possible major different energy sources once and for all. Collecting the data to even attempt to answer the question is inherently very difficult as we cannot readily conduct experiments to answer the question, and sources of data are not collected or consolidated in a manner which can answer this question adequately. 94 The essence of the problem is that most energy industries are not as tightly regulated and monitored to the same degree that say nuclear power or commercial airliners are, so this data is simply not being systematically recorded. However, a number of people have attempted to make estimates. 95 Their conclusions would seem to be that nuclear, wind, and solar are roughly equivalent in terms of safety. All fossil fuels are much less safe than nuclear, wind, and solar, by as much as several orders of magnitude. 96 We can however say with a reasonable degree of certainty that if a country shut down their nuclear power plants and kept their fossil fuel plants, particularly coal, then they probably made their people less safe than if they had done things the other way around. 97 I hope that I have provided some context in which to think about the issue. Thanks again to brian in ohio for providing the question upon which this episode is based. -------------------- Provide feedback on this episode.

Most women who are trying to eat well are getting carbohydrates wrong. Not because they are eating too many, which is what they usually assume. Often because they are eating too few of the right ones and too many of the wrong ones at the wrong times. This week Leanne and Susie break down one of the most misunderstood topics in women's nutrition, what too little carbohydrate actually looks like in the body, what too much of the wrong kind does over time, and how to find the sweet spot that matches your actual activity level, hormones, and goals. Plus, PCOS has a new name. Published in The Lancet in May this year, it is now being referred to as PMOS, and the reason behind the change tells you a lot about how the medical world is finally starting to understand this condition more accurately. In this episode: Why PCOS has been renamed PMOS in a landmark article published in The Lancet, what the name change actually reflects about the condition, and why it matters for the 8 to 13% of women living with it right now The surprising truth about polycystic ovaries: why there are not actually more cysts, and what is really happening in the ovaries of women with this condition Why an anti-inflammatory diet, inositol, and working with a dietitian long-term are central to managing PMOS, and why medication alone will not move the needle the way lifestyle can The signs you are not eating enough carbohydrate: ongoing fatigue despite normal blood tests, poor exercise performance, constant cravings, difficulty concentrating, and never feeling full after meals The signs you are eating too many of the wrong carbohydrates, why the combination of too few quality carbs and too many refined ones is the pattern Leanne and Susie see most consistently in their clinics Why being in carbohydrate no man's land, not low enough for ketosis but not high enough to support metabolism, is one of the most common reasons women stall when trying to lose body fat How carbohydrate needs are highly individual and change depending on body size, activity level, hormones, life stage, and whether you are breastfeeding, perimenopausal, or training intensively The quality carbohydrates to focus on at each meal, and the refined ones that are quietly slipping in while women are avoiding rice at lunch and sweet potato at dinner The new Uncle Tobys Protein Quick Oats reviewed: where the 8 to 9 grams of protein is actually coming from, whether it is enough for women with fat loss or body composition goals, and when Leanne would and would not recommend it The best frozen fish in Australian supermarkets ranked: Sealord, Birdseye, Findus, the Coles wild caught fish fingers, and the steam fresh range reviewed by fish percentage, protein, and taste Work with Leanne or Susie: Winter is one of the best times to work with a dietitian, with fewer social events and more structure. Leanne is at leannewardnutrition.com.au and Susie is at susieburrell.com.au. Shop Designed by Dietitians: Support your protein, creatine, magnesium, and collagen needs with science-backed supplements at designedbydietitians.comSee omnystudio.com/listener for privacy information.

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase dementia risk.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

If you've ever wondered whether your daily walk is actually doing anything for your body, this episode is going to change how you walk for good. We're breaking down Japanese walking, also known as interval walking training, a research-backed method that alternates fast and slow walking in 3-minute bursts, backed by over two decades of peer-reviewed research out of Japan.Alisha Carlson walks through what the research actually shows about blood pressure, blood sugar, leg strength, and bone density, specifically for women over 35 navigating perimenopause, PCOS, or just a body that doesn't respond to exercise the way it used to. No gym. No equipment. No more all-or-nothing thinking. Just a smarter way to walk.What you'll learn:What Japanese walking (interval walking training) actually is, and the simple protocol behind itWhy interval walking improves peak aerobic capacity and leg strength more than walking at one steady paceHow a 10 mmHg drop in blood pressure translates to a real reduction in stroke riskWhat the latest research says about interval walking and bone density in postmenopausal womenWhy cardiorespiratory fitness is one of the strongest predictors of long-term health, and how walking improves itHow to structure your own interval walking routine, including how to break it into smaller chunks if 30 minutes at once isn't realisticThe identity shift that makes a sustainable walking habit actually stickThis episode is for you if...You're a woman over 35 who wants evidence-based movement, not trendsYou're in perimenopause or postmenopause and want to know what actually supports your bones, blood sugar, and blood pressureYou walk regularly already and want to know if a small change could make it more effectiveYou have PCOS or insulin resistance and want a low-barrier way to support blood sugarYou're stuck in the all-or-nothing mindset and want a sustainable, non-diet approach to movementKey research cited:Nemoto et al. (2007), Mayo Clinic Proceedings, 82(7): high-intensity interval walking training improved physical fitness and blood pressure in middle-aged and older adults.Nemoto et al. (2019), Mayo Clinic Proceedings, 679 participants, 5-month IWT study: found a 17% reduction in lifestyle-related disease score and a 14% increase in peak aerobic capacity.Morikawa et al. (2024), PLOS One, 234 postmenopausal women: found improvements in lumbar spine and femoral neck bone density among women with lower baseline bone density.Ettehad et al. (2016), The Lancet, 123 studies, 613,815 participants: every 10 mmHg reduction in systolic blood pressure reduced stroke risk by 27%.The Strong(HER) Way isn't another fitness program, it's a transformation from the inside out. Alisha works with women who are done dieting and done starting over, helping them build a sustainable, healthy relationship with food, their bodies, and movement, without the obsession.Ready to stop starting over? Explore the Fit + Fueled coaching program at thestrongherway.com/fitandfuel or connect on IG @thestrongherway.

On Iran, Hawk recaps the collapse of the Switzerland talks with JD Vance after Trump threatened the Iranian delegation on social media, and raises the point that Lebanon and Israel are not signatories to any negotiations despite being central parties to the ongoing conflict. He also covers the Supreme Court's new gun ruling tied to marijuana use, referencing commentary from Michael Popok, Lisa Graves, and Slate's Dahlia Lithwick and Mark Joseph Stern on Neil Gorsuch's reasoning. Hawk addresses the UFC fighter's remarks about Kamala Harris made at a White House event alongside Joe Rogan, and closes with election analyst Larry Sabato's outlook on 2026 Republican turnout, including Trump's successful primary purges of Thomas Massey, John Cornyn, Bill Cassidy, and Tom Tillis. SUPPORT & CONNECT WITH HAWK- Support on Patreon: https://www.patreon.com/mdg650hawk - Hawk's Merch Store: https://hawkmerchstore.com - Connect on TikTok: https://www.tiktok.com/@mdg650hawk7thacct - Connect on TikTok: https://www.tiktok.com/@hawkeyewhackamole - Connect on BlueSky: https://bsky.app/profile/mdg650hawk.bsky.social - Connect on Substack: https://mdg650hawk.substack.com - Connect on Facebook: https://www.facebook.com/hawkpodcasts - Connect on Instagram: https://www.instagram.com/mdg650hawk - Connect on Twitch: https://www.twitch.tv/mdg650hawk ALL HAWK PODCASTS INFO- Additional Content Available Here: https://www.hawkpodcasts.comhttps://www.youtube.com/@hawkpodcasts- Listen to Hawk Podcasts On Your Favorite Platform:Spotify: https://spoti.fi/3RWeJfyApple Podcasts: https://apple.co/422GDuLYouTube: https://youtube.com/@hawkpodcastsiHeartRadio: https://ihr.fm/47vVBdPPandora: https://bit.ly/48COaTB

CardioNerds (Amit and Dan), Billy Joe Mullinax, and Saahil Jumkhawala discuss the long term management of pulmonary embolism with Dr. Soophia Naydenov.  The episode focuses on the approach to patients who struggle with persistent symptoms like dyspnea and fatigue even after completing the acute phase of anticoagulation. This spectrum of disease, ranging from mild post-PE impairment to chronic thromboembolic pulmonary hypertension (CTEPH), requires a structured follow-up. The discussion covers the critical importance of identifying CTEPH early, the necessary timelines for follow-up, and the appropriate objective screening tools and invasive testing to guide patient care toward full functional recovery. Audio editing by CardioNerds academy intern, Grace Qiu. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Acronyms PE: Pulmonary Embolism PERT: Pulmonary Embolism Response Team CTEPH: Chronic Thromboembolic Pulmonary Hypertension QL: Quality of Life VTE: Venous Thromboembolism DASH: D-dimer, Age, Sex, History of non-provoked PE (a risk score) CPET: Cardiopulmonary Exercise Testing PFTs: Pulmonary Function Tests VQ Scan: Ventilation-Perfusion Scan DOACs: Direct Oral Anticoagulants TPA: Tissue Plasminogen Activator (Thrombolytics) ECMO: Extracorporeal Membrane Oxygenation Pearls: Post-PE “Syndrome” is a Spectrum: It is more accurately a spectrum of disease (sequelae of PE) rather than a single syndrome, ranging from mild fatigue/dyspnea to the most severe form, CTEPH. Structured Follow-up is Mandatory: All PE survivors need a structured follow-up, typically with checkpoints at 3, 6, 12, and 16–24 months, with the primary goal being to detect CTEPH, the deadliest, yet potentially curable, disease on the spectrum. Screening Should Be Objective and Practical: When screening for persistent symptoms, use objective assessment tools like the Post-VTE Functional Status (PVFS) scale or the Modified Medical Research Council (MMR-C) scale, as highly comprehensive but cumbersome tools (like the PE Quality of Life questionnaire) may not be practical for routine clinical use. Recurrence Risk Scores Aid in Anticoagulation Duration: Simple scores like the DASH score or the HERDO2 score (for women) can provide guidance when considering the continuation versus discontinuation of anticoagulation after the initial treatment phase. Invasive Testing for Persistent Symptoms: If a patient remains symptomatic at the 6-month mark despite normal non-invasive testing (chest X-ray, ECG, PFTs, six-minute walk, echo, VQ scan, CPET), consider invasive testing such as Right Heart Catheterization (RHC) at rest or with exercise, or an invasive CPET. Notes: Notes drafted by Saahil Jumkhawala. 1. The Spectrum of Post-PE Disease The term “post-PE syndrome” should be used with caution, as it refers to a spectrum of disease rather than a single entity. This spectrum includes symptoms (sequelae) that exist in a patient’s life following an incidental PE event that they did not have before. On one extreme is Chronic Thromboembolic Pulmonary Hypertension (CTEPH): The definition is clear, but it is the most deadly type, though thankfully rare (2% to 4%). It involves a residual clot and pulmonary hypertension identifiable at rest. In the middle is Chronic Thromboembolic Disease (CTED): Patients may have residual defects seen on a VQ or CT scan, but they do not have pulmonary hypertension. On the other side is a milder disease, which can include fatigue, dyspnea, or a patient’s perceived impairment, where the definitions of CTEPH and CTED are not met, but the patient remains symptomatic. 2. Structured Follow-up and Screening for Post-PE Symptoms Structured follow-up is key for all PE survivors, though the structure may vary based on available resources (PCP, Cardiology, Pulmonary, or multidisciplinary clinic). Recommended Timeline for Follow-up: Data from studies like ELOPE and FOCUS suggest checkpoints at 3, 6, 12, and up to 16 to 24 months. This timeline is designed to identify patients who may develop CTEPH. 88% of patients who develop CTEPH will be identified within about a year. A structured follow-up can reduce the delay in CTEPH diagnosis from 10–12 months to 4–6 months. Personal Practice Note: A quick 2–3 week/30-day check-in is recommended for severely ill patients (e.g., those who had TPA, profound shock, or ECMO support) to ensure medication compliance, manage symptoms, and identify red flags. Screening Tools (Objective Assessment): The first step is an inventory of patient symptoms, leaning toward objective rather than subjective assessment. Recommended Simple Tools: Modified Medical Research Council (MMR-C) for dyspnea evaluation. Post-VTE Functional Status (PVFS) scale. The Pulmonary Embolism Quality of Life (QL) questionnaire is comprehensive but long, making it tedious and better suited for research. Future Utility: Technology (AI/electronic tools) may assist in administering these questionnaires before the clinic visit, presenting the information as a “dashboard” for the provider. 3. Management of Persistent Symptoms and Further Testing Initial Non-Invasive Tests (Often done at 3 months): Echocardiogram VQ Scan Full PFTs Six-minute walk CPET Further Evaluation for Persistent Symptoms (e.g., at 6 months): If non-invasive tests (Chest X-ray, ECG, CPET) are normal but symptoms persist, more invasive testing should be considered as the patient has not returned to baseline. Repeat VQ scan or echocardiogram if symptoms have changed. Right Heart Catheterization (RHC) at rest or with exercise. Invasive CPET. PA gram (Pulmonary Angiogram) to assess vasculature. 4. Recurrence Risk and Anticoagulation Duration The decision to continue or discontinue anticoagulation depends on the patient’s risk factors, the situation of the PE (provoked or unprovoked), presence of active cancer, and patient preference. Recurrence Risk Scores: Simple scores are preferred for practicality. DASH Score. HERDO2 Score (particularly for women). The Vienna Score can be considered if the question is whether to restart anticoagulation after a disruption. Role of D-dimer in Abbreviation: While D-dimer can be used to guide the decision to restart anticoagulation after a planned pause (if D-dimer is high, resume), patient symptoms are preferable to guide management decisions like early abbreviation. 5. Prevention of Post-PE Syndrome Currently, there is no clear tool known to prevent the post-PE syndrome/spectrum of disease. Best Current Advice for Prevention/Recovery: Anticoagulation compliance. Pulmonary rehabilitation, which aids in faster recovery. General precautions, such as smoking cessation and body weight management. Future Research: Ongoing trials are investigating whether acute management strategies (e.g., using thrombolytics in intermediate-risk PE) can prevent long-term sequelae. (The PYTHO trial did not show a reduced rate of CTEPH in intermediate-risk PE patients who received thrombolytics). References: Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. “Venous Thromboembolism.” The Lancet, vol. 398, no. 10294, 2021, pp. 64-77. doi:10.1016/S0140-6736(20)32658-1. Kearon, C., & Kahn, S. R. “Long-Term Treatment of Venous Thromboembolism.” Blood, vol. 135, no. 5, 2020, pp. 317-325. doi:10.1182/blood.2019002364. Kahn, S. R., & de Wit, K. “Pulmonary Embolism.” The New England Journal of Medicine, vol. 387, no. 1, 2022, pp. 45-57. doi:10.1056/NEJMcp2116489. Di Nisio, M., van Es, N., & Büller, H. R. “Deep Vein Thrombosis and Pulmonary Embolism.” The Lancet, vol. 388, no. 10063, 2016, pp. 3060-3073. doi:10.1016/S0140-6736(16)30514-1. Chopard, R., Albertsen, I. E., & Piazza, G. “Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review.” JAMA, vol. 324, no. 17, 2020, pp. 1765-1776. doi:10.1001/jama.2020.17272.

Episode OverviewFor the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Professor Charles Herbaux to unpack the data, debate the clinical implications, and ask the question that's on every hematologist's mind: is this enough to change practice?Background: Setting the Stage for TafasitamabBefore diving into frontMIND, the episode provides context on tafasitamab, a CD19-targeting monoclonal antibodyL-MIND (Phase 2 — relapsed/refractory DLBCL):81 patients with R/R DLBCLORR 58%, complete response rate 41%Established activity of tafasitamab + lenalidomide in the relapsed settinghttps://pubmed.ncbi.nlm.nih.gov/32511983/First-MIND (Phase 1b — frontline DLBCL, IPI 2–5):66 patients randomized: tafa-R-CHOP (n=33) vs. tafa-len-R-CHOP (n=33)ORR: 75.8% vs. 81.8%, respectivelySerious treatment-emergent adverse events: 42.4% vs. 51.5%Provided the signal (and the safety caution) to move to phase 3https://pubmed.ncbi.nlm.nih.gov/37369099/The frontMIND TrialDesign: Phase 3, double-blind, placebo-controlled randomized trialIntervention: R-CHOP + tafasitamab (12 mg/kg IV days 1, 8, 15 per cycle) + lenalidomide (25 mg/day, days 1–10 per cycle)Control: R-CHOP + placebosGCSF mandatory (given double-blind design); VTE prophylaxis (heparin or aspirin) mandatory given lenalidomideEnrollment: May 2021 – March 2023; 899 patients randomizedPrimary endpoint: Investigator-assessed progression-free survival (PFS)Patient Population:Age 18–80; DLBCL or high-grade B-cell lymphoma, IPI 3–5Median age: 65 years96% advanced stage; 54% bulky disease; 31% ECOG PS 2; 82% elevated LDH55% IPI 3 / aaIPI 2; 43% IPI 4–5 / aaIPI 38% double/triple hit — a high-risk subgroup included despite R-CHOP being the controlBroad histologic inclusion: transformed lymphoma, grade 3B FL, T-cell/histiocyte-rich LBCL, EBV+ DLBCL, ALK+ LBCL, HHV8+ DLBCL Note: On retrospective central review, ~7% of patients had a different histology (roughly half had FL grade 1–3A), underscoring the diagnostic challenges in DLBCL~40% received pre-phase steroids; 8% rituximab; 4% vincristine prior to cycle 1Key Efficacy Results(Primary analysis at median follow-up 35.2 months) | Endpoint | Tafa-Len-R-CHOP | R-CHOP | HR / p-value | 2-year PFS | 71.1% | 62.9% | HR 0.75, p=0.0194 | 3-year PFS | 67.3% | 60.7% | ~6.6% absolute difference | Overall Survival | — | — | HR 0.85, p=0.27 (immature)Points of Discussion:Absolute PFS benefit at 2 years: ~8.2%; at 3 years: ~6.6% — a modest but statistically significant improvementOS curves cross early, then separate slightly from ~18 months; data remain immatureEarly censoring observed: ~17% (intervention) and ~14% (control) censored by 9 months — raises questions about off-protocol therapySubgroup consistency: PFS benefit appeared consistent across prespecified subgroups; specific subgroups discussed in the episodeSafety Adverse Event | Tafa-Len-R-CHOP | R-CHOP | Fatal treatment-emergent AEs | 6% (26 pts) | 4% (17 pts) | Diarrhea (any grade) | 25% | 17% | Febrile neutropenia | 17% (incl. 1 death) | 13% | Grade ≥3 anemia | 24% | 17% | Grade ≥3 thrombocytopenia | 27% | 14%The addition of tafasitamab and lenalidomide to R-CHOP adds meaningful hematologic toxicity, particularly thrombocytopenia and anemia, as well as diarrhea and febrile neutropenia.Key Discussion Points from the EpisodeDid the early-phase L-MIND and First-MIND data justify bringing tafasitamab into the front-line setting, and was tafa-len-R-CHOP the right intervention arm to take forward?Is R-CHOP the appropriate control for a patient population that includes 8% double/triple hit lymphoma?What are the implications of using investigator-assessed PFS as the primary endpoint — and how critical is effective blinding to the integrity of that endpoint?How do we interpret the early OS curve crossing and currently non-significant OS benefit?Is the ~8% absolute PFS improvement at 2 years clinically meaningful enough to change practice — particularly given the added toxicity?How should we think about patient selection: who would you prioritize for tafa-len-R-CHOP over standard R-CHOP in clinical practice?What does frontMIND mean for the DLBCL treatment landscape alongside polatuzumab-R-CHP (POLARIX)?Resources & Further ReadingfrontMIND trial: Lenz et al. Lancet. https://pubmed.ncbi.nlm.nih.gov/42217458/POLARIX: Tilly H, et al. NEJM 2022About BloodCancerTalksBloodCancerTalks is a medical education podcast hosted by Raj, Ashwin, and Eddie, dedicated to the latest advances in hematologic malignancies. New episodes available wherever you listen to podcasts.Follow us on X/Twitter for episode updates and hematology/oncology content. 

In this episode of PICU Doc on Call, hosts Dr. Monica Gray and Dr. Pradip Kamat explore procedural sedation in the pediatric ICU. They cover sedation levels, pre-screening, risk stratification using ASA classifications, and medication selection tailored to each patient's hemodynamic and respiratory status. Through real-world case discussions involving respiratory failure, septic shock, and acute neurological decline, they highlight the importance of end-tidal CO2 monitoring and early adverse event recognition. Key takeaways include avoiding the term "conscious sedation," preparing rescue plans, and prioritizing patient safety through careful assessment and monitoring.Show Highlights:Definitions and levels of sedation (minimal, moderate, deep sedation, and general anesthesia)Importance of terminology in procedural sedationMonitoring sedation levels using scales like the Richmond Agitation-Sedation Scale (RASS)Pre-screening and risk stratification considerations for pediatric patientsASA physical status classification system for assessing patient riskUnique challenges of procedural sedation in critically ill childrenAdverse events associated with pediatric procedural sedation, particularly respiratory complicationsManagement strategies for specific cases requiring sedation (e.g., respiratory failure, septic shock)Importance of end-tidal CO2 monitoring during sedationKey takeaways for safe sedation practices in the pediatric ICU settingReferences: Nir Atlas; Rahul C. Damania; Pradip P. Kamat In Fuhrman & Zimmerman - Textbook of Pediatric Critical Care Chapter 135, 1624-1628Statement on Continuum of Depth of Sedation: Definition of General Anesthesia and Levels of Sedation/Analgesia by Committee on Quality Management and Departmental Administration. Last Amended: October 23, 2024.Coté CJ, Wilson S; AMERICAN ACADEMY OF PEDIATRICS; AMERICAN ACADEMY OF PEDIATRIC DENTISTRY. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures. Pediatrics. 2019 Jun;143(6):e20191000. doi: 10.1542/peds.2019-1000. PMID: 31138666.xKrauss B, Green SM. Procedural sedation and analgesia in children. Lancet. 2006 Mar 4;367(9512):766-80. doi: 10.1016/S0140-6736(06)68230-5. PMID: 16517277.Sharif S, Kang J, Sadeghirad B, Rizvi F, Forestell B, Greer A, Hewitt M, Fernando SM, Mehta S, Eltorki M, Siemieniuk R, Duffett M, Bhatt M, Burry L, Perry JJ, Petrosoniak A, Pandharipande P, Welsford M, Rochwerg B. Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials. Br J Anaesth. 2024 Mar;132(3):491-506. doi: 10.1016/j.bja.2023.11.050. Epub 2024 Jan 6. PMID: 38185564.Smith, Heidi A. B. MD, MSCI (Chair)1,2; Besunder, James B. DO, FCCM3,4; Betters, Kristina A. MD1; Johnson, Peter N. PharmD, BCPS, BCPPS, FCCM, FPPA, FASHP5,6; Srinivasan, Vijay MBBS, MD, FCCM7,8; Stormorken, Anne MD9,10; Farrington, Elizabeth PharmD, FCCM11; Golianu, Brenda MD12,13; Godshall, Aaron J. MD14; Acinelli, Larkin CPNP-AC, ACHPN15; Almgren, Christina CPNP16; Bailey, Christine H. MD17; Boyd, Jenny M. MD18,19; Cisco, Michael J. MD20; Damian, Mihaela MD, MPH21,22; deAlmeida, Mary L. MD23,24; Fehr, James MD13,25; Fenton, Kimberly E. MD, FCCM14; Gilliland, Frances DNP, CPNP-AC/PC26,27; Grant, Mary Jo C. CPNP-AC, PhD, FAAN28; Howell, Joy MD29; Ruggles, Cassandra A. PharmD, BCCCP, BCPPS30; Simone, Shari DNP31,32; Su, Felice MD21,22; Sullivan, Janice E. MD33,34; Tegtmeyer, Ken MD, FAAP, FCCM35,36; Traube, Chani MD, FCCM29; Williams, Stacey CPNP-AC37; Berkenbosch, John W. MD, FAAP, FCCM (Chair)33,34. 2022 Society of Critical Care Medicine Clinical Practice Guidelines on Prevention and Management of Pain, Agitation, Neuromuscular Blockade, and Delirium in Critically Ill Pediatric Patients With Consideration of the ICU Environment and Early Mobility. Pediatric Critical Care Medicine 23(2):p e74-e110, February 2022. | DOI: 10.1097/PCC.0000000000002873Benzoni T, Agarwal A, Cascella M. Procedural Sedation. [Updated 2025 Mar 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551685/Kerson AG, DeMaria R, Mauer E, Joyce C, Gerber LM, Greenwald BM, Silver G, Traube C. Validity of the Richmond Agitation-Sedation Scale (RASS) in critically ill children. J Intensive Care. 2016 Oct 26;4:65. doi: 10.1186/s40560-016-0189-5. PMID: 27800163; PMCID: PMC5080705.Tel-Dan SF, Shavit D, Nates R, Samuel N, Shavit I. Emergency Physician-Administered Sedation for Thoracostomy in Children With Pleuropneumonia. Pediatr Emerg Care. 2021 Dec 1;37(12):e1209-e1212. doi: 10.1097/PEC.0000000000001975. PMID: 31929389.Cosgrove P, Krauss BS, Cravero JP, Fleegler EW. Predictors of Laryngospasm During 276,832 Episodes of Pediatric Procedural Sedation. Ann Emerg Med. 2022 Dec;80(6):485-496. doi: 10.1016/j.annemergmed.2022.05.002. Epub 2022 Jun 23. PMID: 35752522.Cravero JP, Blike GT, Beach M, Gallagher SM, Hertzog JH, Havidich JE, Gelman B; Pediatric Sedation Research Consortium. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics. 2006 Sep;118(3):1087-96. doi: 10.1542/peds.2006-0313. PMID: 16951002.

In this episode of Keeping Abreast, Dr. Jenn Simmons responds to Peter Attia's breast cancer screening episode (#396). Attia asks the right question: why are 42,000 women still dying of breast cancer every year? But his answer, more mammograms and MRI on top, is exactly wrong. Dr. Jenn breaks down, study by study, why that 40-year approach has never moved the death toll.Forty-two thousand women a year. That number has not moved since mammography went mainstream in the 1980s. Detection rates are up, diagnoses are up, and the death toll has not changed. We have been finding more cancer, calling more women patients, and watching the same number of them die. If you have ever scheduled your annual mammogram believing it was the most protective thing you could do, this episode will reframe everything you thought you knew.What You'll LearnWhy the breast cancer death toll has not moved in 40 years, and why more screening is the reasonWhy DCIS is not cancer, why mammography invented it, and what happens to a woman the moment it gets labeled "stage zero"Why an aggressive tumor is aggressive from the day it forms, and why finding it earlier on a mammogram does not change what it does nextWhy mammography catches the cancers least likely to kill you, and routinely misses the ones that willWhat happened when researchers followed 89,835 women for 25 years and compared annual mammography to doing nothing, and why you have never heard about itWhat the Cochrane review found after analyzing every randomized mammography trial ever run, and why Peter Attia addressed it in one sentenceWhy the WISDOM trial, the most significant recent evidence in this space and the one study Attia never mentions, is an indictment of everything he arguedWhy there is no standard radiation dose for a mammogram, and why the woman next to you in the waiting room may have received ten times less than you didWhat the FDA has formally documented about gadolinium staying in the brain and bones for years, and why the women being told to get it every six months are the last women who shouldWhy insulin resistance, chronic inflammation, and toxic burden are among the most powerful drivers of breast cancer risk, and why Attia's episode contained zero mention of any of themResources MentionedPeter Attia, Episode 396 on breast cancer screening: peterattiamd.com/breastcancerscreeningDr. Robin Berzin, founder of Parsley HealthMiller AB, et al. Twenty five year follow-up of the Canadian National Breast Screening Study. BMJ. 2014;348:g366.Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;(6):CD001877.Zahl PH, et al. Results of the Two-County trial are not compatible with official Swedish breast cancer statistics. Danish Medical Bulletin. 2006;53(4):438–440.Nyström L, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909–19.Esserman LJ, et al. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA. 2026;335(9):763–774.FDA gadolinium-based contrast agent safety communications (2015, 2017, 2018), summarized in Fotenos A, FDA Pediatric Advisory Committee, Sept 2018.Kanda T, et al. High signal intensity in the dentate nucleus and globus pallidus and cumulative gadolinium dose. Radiology. 2014;270(3):834–841.Veenhuizen SGA, et al. Supplemental breast MRI for women with extremely dense breasts: DENSE trial. Radiology. 2021;299(2):278–286.Tabar L, et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet. 1985;325:829–32.To talk to a member of Dr. Jenn's team and learn more about working privately with Dr. Jenn visit: https://calendly.com/stephanie-1031/clarity-callTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.jennsimmonsmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

Welcome back to the show, everybody! Today, we are diving deep into the intersection of maternal-fetal medicine and cardiology. We're tackling a condition that keeps every OB/GYN, MFM, and cardiologist up at night: Peripartum Cardiomyopathy, or PPCM. And to keep our clinical gears turning, we are framing this discussion squarely through the lens of Society for Maternal-Fetal Medicine (SMFM) Consult Series #73, which focuses on right and left heart failure in pregnancy, alongside the foundational data from ACOG Practice Bulletin #212. PPCM presents fundamentally as acute left heart failure with reduced ejection fraction. Think of the left ventricle as the primary engine pump of the systemic circulation. When it stalls, everything upstream gets backed up. While this was traditionally called IDIOPATHIC, newer data says otherwise. We are going to cover presentation, eval, care and prognosis. So, get your palpitations in check- here we go. 16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. SMFM CS 73; 20252. ACOG PB 212; 20193. Arany Z. Peripartum Cardiomyopathy. The NEJM. 2024. 4. Sliwa K, Hilfiker-Kleiner D, Damasceno A, Al Farhan H, Goland S, Johnson MR, Bauersachs J. Peripartum cardiomyopathy. Lancet. 2025 Nov 22;406(10518):2483-2493. doi: 10.1016/S0140-6736(25)01451-5. Epub 2025 Oct 28. PMID: 41173010.

Geriatrician Dr. Mark Supiano joins the podcast to discuss the connection between heart and brain health. Citing multiple clinical trials, he breaks down what these studies and their findings mean for blood pressure management's effect on cognitive decline and how they directly impact both patients and clinicians. Guest: Mark A. Supiano, MD, geriatrician, University Hospital Geriatrics Clinic, professor, Internal Medicine, Utah School of Medicine Show Notes Read about the Systolic Blood Pressure Intervention Trial (SPRINT) Study on the National Heart, Lung, and Blood Institute website. Learn about the SPRINT MIND study in the Journal of the American Medical Association.  Read Dr. Supiano's study, “Hypertension in the Oldest Old,” published by the Journal of the American College of Cardiology: Advances on their website. Learn about the HYVET, STEP, SPRINT-HEART and China Rural Hypertension Control Project studies through their articles on the National Library of Medicine website. Learn about an ancillary study to SPRINT, “Changes in arterial stiffness under blood pressure control are independently associated with cognitive impairment,” on the National Library of Medicine website. Learn about the Systolic Hypertension in the Elderly Program (SHEP) study, published by Clinical and Experimental Hypertension, on the Taylor and Francis Online website. Learn about the ESPRIT study on The Lancet website. Learn more about Dr. Supiano on the University of Utah Health website.   Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia.

Chaque jour, en moins de 10 minutes, un résumé de l'actualité du jour. Rapide, facile, accessible.

☎️ Book Your COMPLEMENTARY CONSULTATION and CALORIE CALCULATION Call: https://calendly.com/d/2p8-mxx-dgf/free-consultation-call-zoom⁠⁠⁠⁠⁠⁠PMOS guide: https://www.vitalityoet.com/pmosPCOS has officially been renamed PMOS - Polyendocrine Metabolic Ovarian Syndrome - published in The Lancet on May 12th, 2026, after 14 years of global collaboration. In this episode I share my own PMOS story - cortisol-induced, stress-driven, and masked by birth control for years.  What You'll LearnWhy PCOS was renamed PMOS and what each word in the new name actually meansStephanie's personal cortisol-driven PMOS story — and how birth control masked it for yearsWhat PMOS actually is, explained simply — androgens, the hormonal system, why symptoms happenThe four types of PMOS: insulin-resistant, adrenal/cortisol, inflammatory, and post-pillThe specific tests that reveal each type — including why fasting glucose misses most of themWhy the same diagnosis needs four different solutionsWhat the first move is for each type

Ryan & Mike take on ADHD kids' medication based on research and doctors, not social media. They cover untreated ADHD risks, debunk the psychiatrist myth, and put decisions with parents and prescribers.Find Mike @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.grownowadhd.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Ryan @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.adhddude.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠{{chapters}}[00:00:00] Start[00:01:05] Why Parents Get Confused About Medication[00:03:40] The Risks of Untreated ADHD[00:06:46] Where Medication Misinformation Comes From[00:10:15] Do You Really Need a Child Psychiatrist?[00:13:34] Who Makes the Medication DecisionCitationsAmerican Academy of Child and Adolescent Psychiatry. (2020). Clinical use of pharmacogenetic tests in prescribing psychotropic medications for children and adolescents. https://www.aacap.org/aacap/Policy_Statements/2020/Clinical-Use-Pharmacogenetic-Tests-Prescribing-Psychotropic-Medications-for-Children-Adolescents.aspxAmerican Academy of Child and Adolescent Psychiatry. (2022). Attention-deficit/hyperactivity disorder: Parents' medication guide. https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/ADHD_Medication_Guide-web.pdfAmerican Academy of Child and Adolescent Psychiatry. (n.d.). Pharmacogenetic testing. https://www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/FFF-Guide/Pharmacogenetic_Testing-128.aspxAmerican Psychiatric Association. (n.d.). What is ADHD? https://www.psychiatry.org/patients-families/adhd/what-is-adhdCenters for Disease Control and Prevention. (2024). Clinical care of ADHD. https://www.cdc.gov/adhd/hcp/treatment-recommendations/index.htmlDalsgaard, S., Leckman, J. F., Mortensen, P. B., Nielsen, H. S., & Simonsen, M. (2015). Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: A prospective cohort study. The Lancet Psychiatry, 2(8), 702–709. https://doi.org/10.1016/S2215-0366(15)00271-0Dalsgaard, S., Østergaard, S. D., Leckman, J. F., Mortensen, P. B., & Pedersen, M. G. (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. The Lancet, 385(9983), 2190–2196. https://doi.org/10.1016/S0140-6736(14)61684-6de Vries, W., Boer, M., Stevens, G. W. J. M., & van Dorsselaer, S. (2025). Exploring concept creep: Youth's portrayal of ADHD on TikTok. SSM Mental Health, 7, 100374.Harpin, V., Mazzone, L., Raynaud, J. P., Kahle, J., & Hodgkins, P. (2016). Long-term outcomes of ADHD: A systematic review of self-esteem and social function. Journal of Attention Disorders, 20(4), 295–305. https://doi.org/10.1177/1087054713486516Myer, N. M., Boland, J. R., & Faraone, S. V. (2018). Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Molecular Psychiatry, 23, 1929–1936.Shaw, M., Hodgkins, P., Caci, H., Young, S., Kahle, J., Woods, A. G., & Arnold, L. E. (2012). A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: Effects of treatment and non-treatment. BMC Medicine, 10, 99. https://doi.org/10.1186/1741-7015-10-99Wetterer, L. (2020). Attention-deficit/hyperactivity disorder: AAP updates guideline for diagnosis and management. American Family Physician, 102(1), 58–60.Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528Yeung, A., Ng, E., & Abi-Jaoude, E. (2022). TikTok and attention-deficit/hyperactivity disorder: A cross-sectional study of social media content quality. The Canadian Journal of Psychiatry, 67(12), 899–906. https://doi.org/10.1177/07067437221082854

Aaron Brown is a quantitative analyst, risk manager, and author of the new book Wrong Number: How to Extract Truth from a Blizzard of Quantitative Disinformation. https://amzn.to/4frmg3n He's also about to debate gun control at the Soho Forum in August — and his preparation for that debate is a pretty good preview of what's in the book. Topics include: why out of 28,000 gun control studies, the RAND Corporation found only 20 that weren't statistically crippled; the smoking analogy and what it tells us about legislation that runs ahead of evidence; why gun laws burden legitimate owners and not criminals; why we have a crime problem, not a gun problem; The Lancet paper that claimed US aid saved 92 million lives; how to spot three red flags that tell you a statistic is BS; and Wonder Bread's motto "Helps build strong bodies 12 ways" — which nobody ever actually wrote down. Get the book → Wrong Number: How to Extract Truth from a Blizzard of Quantitative Disinformation https://amzn.to/4frmg3n TIMESTAMPS: 0:00 — Intro — Aaron Brown and Wrong Number 0:34 — The Soho Forum gun control debate — and who he's up against 3:45 — The proposition: abolish all restrictions on adult firearm ownership 4:48 — Lou on navigating gun laws across state lines (NJ → PA → NY) 7:25 — The wide cultural divide: Scranton airport vs. any other airport with guns 9:04 — RAND Corporation: of 28,000 gun control studies, only 20 weren't crippled by errors 10:04 — The smoking analogy — legislation running ahead of the evidence 12:15 — Gun control laws only burden legitimate owners — not criminals 12:43 — The Glock switch ban and the AR-15 — targeting the popular, not the dangerous 15:18 — "Trump is a fascist" — and you want him to take the guns? 15:42 — Stop calling it a gun problem. It's a crime problem. 17:47 — We can identify the 1% of kids likely to commit 20–30% of violent crime 19:31 — Genetic markers for violence — and why that's controversial 20:48 — The Nordic prison model — does it work, and could it work here? 22:09 — Immigration data: why lumping everyone together gets you bad answers 25:20 — Lou's joke about open borders (for immigrants like his dad, not his cousins) 25:39 — Aaron's Jewish smuggler ancestors — blocked from junk dealing by licensing laws 27:04 — Did US aid really save 92 million lives? The Lancet paper that can't add up 29:13 — They saved 114% of the people — including 46M in China, which gets no aid 31:22 — Most published research findings are false — and we've known since 2005 32:42 — DOGE cuts and the "millions are dead" narrative 36:15 — Three red flags that tell you a statistic is BS 39:18 — Wonder Bread's "12 ways" — nobody ever wrote them down 40:18 — Outro — Wrong Number and the Soho Forum debate Watch full episodes on YouTube → https://www.youtube.com/watch?v=J4Vb53s4I0A&list=PLb5trMQQvT077-L1roE0iZyAgT4dD4EtJ Listen on Apple Podcasts → https://podcasts.apple.com/us/podcast/the-lou-perez-podcast/id1535032081 Listen on Spotify → https://open.spotify.com/show/2KAtC7eFS3NHWMZp2UgMVU  Lou's book — That Joke Isn't Funny Anymore: https://amzn.to/3VhFa1r  TheLouPerez.com |  info@thelouperez.com  Newsletter: https://substack.com/@louperez #Statistics #Misinformation #GunControl #USAID #AaronBrown #WrongNumber #SohoForum #LouPerezPodcast #LionsOfLiberty #DataLiteracy Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode#337-Taped April 29, 2026 We talk about vaccines, pandemic preparedness and emerging infectious diseases. Vaccines remain one of the most powerful public health tools that we have. A 2024 Lancet study estimated that global immunization efforts saved 154 million lives over the past 50 years- that's about 6 lives every minute. Joining us is Dr. Amesh Adalja MD, a board-certified infectious diseases, critical care, emergency medicine, senior scholar at the Johns Hopkins Center for Health Security. He is also an affiliate of the Johns Hopkins Center for Global Health. Dr. Adalja will discuss with us evidence-based insights on vaccines and their importance in our lives and health and well-being. Are we pandemic prepared? And what can we do as individuals to protect ourselves and have long-term health protection. To get in touch with Amesh Adalja MD and learn all about him and his work, go to www.ameshadalja.com Check out Dr. Amesh Adalja www.ameshadalja.com It's All About Health & Fitness-Vicki Doe Fitness podcast Ranked on the Top 25 Midwest Fitness Podcasts to Listen to… with additional national recognition on the Top 100 US fitness podcast. Rate This Podcast Give us a 5-star review.  We appreciate you! Take this quick audience survey. Thank you! FREE Metabolic Makeover Masterclass Webinar Replay! Learn how to reset your metabolism, boost energy, and support sustainable weight loss using simple, science-backed strategies. Enroll in the Vicki Doe Fitness Academy to get instant access to the replay and begin your healthy living journey today. Vicki Doe Fitness-STORE Discover the Vicki Doe Fitness-STORE—your destination for stylish apparel, fitness gear, and wellness essentials like yoga mats, water bottles, candles, and premium supplements. Shop now and elevate your health journey! Resources *Note: Some of the resources below may be affiliate links, meaning Vicki Doe Fitness receives a commission (at no extra cost to you) if you use the link to make a purchase. Thank you for your support! Herbs and spices are the keys to delicious, flavorful, and sophisticated meals! FREE DOWNLOAD- Herbs and Spices Cheatsheet Let's get ECO-friendly.  Try ECOLunchbox.com ECOlunchbox specializes in stainless steel bento boxes, artisan fair trade lunch bags, napkins, snack sacks, and other eco-friendly lunchware. They are a certified green business.  ECOlunchbox is a consumer products company started by an eco mom in the San Francisco Bay Area. ECOLunchbox.com Go to our Resources page-   For the most recommended tools, you need to succeed on your healthy living journey!! Listen and share our podcast show- “It's All About Health & Fitness-” Vicki Doe Fitness Subscribe to Apple Podcast Subscribe on Stitcher Or on any of the platforms that you listen to your podcast! Watch & Subscribe on YouTube! Catch our latest health & wellness videos on YouTube at Vicki Haywood Doe – Vicki Doe Fitness YouTube-Vicki Haywood Doe-Vicki Doe Fitness Join us to receive a health wellness message!

Get Myoscience Creatine and Magnesium (20% off) HERE: https://bit.ly/4ocjMbp  Pre-order Keto Flex Revised and get free bonuses: https://bit.ly/4wKG1sM    Men today are walking around with 20 to 30% less testosterone than their fathers had at the exact same age. Not because of disease. Because of five everyday habits that modern men think are completely normal. In this episode, I'm breaking down the five silent mistakes that are aging men faster than anything else right now, the science behind why they're so damaging, and the exact daily stack I personally use to fight back. I'm 41 years old and I've watched this happen to men I love. The decline doesn't announce itself. But it can be reversed. Key Takeaways: Men today have 20 to 30% less testosterone than men of the same age in 1988, per the Massachusetts Male Aging Study Grip strength predicts death more accurately than blood pressure, per a Lancet meta-analysis of 140,000 people One week of sleeping 5 hours or less drops testosterone by 10 to 15%, the equivalent of aging 10 to 15 years Sitting for long hours thins the memory center of the brain, and exercise does not offset this damage 85-year-olds gained muscle and reversed fiber-level aging in 12 weeks of resistance training in a Mayo Clinic study The five mistakes: stopping explosive movement, stopping brain challenges, ignoring muscle decline, neglecting recovery, and accepting decline as normal The simple daily stack: outdoor walks, heavy lifting twice a week, one gram of protein per pound of ideal body weight, 7+ hours of sleep, creatine, magnesium, and weekly brain challenges Find All The Ben Azadi Show Sponsorship Deals ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.ketokamp.com/sponsorship-deals Learn more about your ad choices. Visit megaphone.fm/adchoices

A guide to diagnosing, imaging, and managing acute renal colic and nephrolithiasis in the ED. Hosts: Brian Gilberti, MD Avir Mitra, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Nephrolithiasis.mp3 Download Leave a Comment Tags: Kidney Stones, Urology Show Notes 1. CLINICAL CORE & PHYSIOLOGIC FRAMEWORK Epidemiologic Risk Profiles Lifetime incidence parameters hover around 1 in 11, presenting with a prominent male sex skew. Peak demographic manifestation concentrated within the 30–60 age band. High-yield temporal parameter: 50% recurrence vector within a 5-year post-initial-insult window. Mineralogical Composition Vectors Calcium oxalate crystals represent the predominant structural matrix. Struvite configurations (magnesium ammonium phosphate matrix) account for 1–2% of cohorts. Struvite stones function explicitly as infection-driven configurations secondary to upper tract proliferation; higher distribution index noted in female cohorts. Etiological & Modifiable Relational Dynamics Profound systemic dehydration or low baseline fluid throughput states. High-sodium diet structures and heavy animal-protein consumption loads. Positive genetic/familial history variables. Relative risk modulation: Each variable independently operates to expand baseline risk by a factor of 2x to 3x. Pathophysiologic Symptom Complexes Acute, sudden-onset, maximum-intensity (10/10) unilateral flank pain. Classic structural radiation vector tracking downward toward the ipsilateral groin/genitourinary dermatomes. Distinctive behavioral marker: Renal colic pacing/writhing behavior with zero antalgic position availability. Concomitant autonomic triggers: Nausea and emesis manifest in 50% of acute presentations. Physical Exam Discordance Metrics Severe subjective distress contrasted with a characteristically soft, completely non-tender abdominal palpation exam. CVA tenderness is completely variable and lacks reliable negative predictive value. Atypical Presentation Classifications Vague, poorly localized abdominal pain presentations occurring in up to 20% of active cases. Isolated lower urinary tract irritative signs including acute frequency or severe urgency. Incidental & Asymptomatic Dynamics Silent intrarenal or ureteral stones found incidentally. Longitudinal tracking demonstrates up to 33.3% of initially asymptomatic cohorts convert to fully symptomatic renal colic within a multi-year tracking window. 2. EXCLUSION DIAGNOSES & CRITICAL PATHWAY RED FLAGS Vascular Mimics: AAA rupture/expansion. This is a mandatory exclusion pathway in elderly cohorts presenting with acute flank or back pain. Physical tracking requires active exploration for an expansile, pulsatile abdominal mass. Gynecologic Emergencies: Ruptured ectopic pregnancy. Demands universal screening protocols via rapid beta-hCG testing in all female patients of childbearing potential presenting with lower abdominal/pelvic localization. Infectious Upper Tract Decompensation: Acute uncomplicated pyelonephritis. Differentiated via persistent high spikes, high fevers, systemic shaking chills, and profound pyuria. Genitourinary Structural Crises: Acute testicular torsion. Mandates a thorough, explicit scrotal/testicular structural exam if the flank pain radiates into the scrotum. Gastrointestinal and Adnexal Torsional Confounds: Acute appendicitis variants, acute mesenteric/bowel ischemia, and ovarian torsion syndromes. 3. LABORATORY TESTING & PHYSIOLOGIC EVALUATION Urinalysis Interpretation Nuances Microscopic or gross hematuria presents in approximately 66% to 90% of acute cases. Critical Pathological Caveat: Complete absence of hematuria documented in 20% to 33.3% of confirmed, acute obstructing ureteral stones. Diagnostic rule: A pristine urinalysis with zero red blood cells is entirely insufficient to exclude acute ureterolithiasis. Urinary pH as a Composition Clue Consistently low urinary pH parameters (pH < 5.5) point strongly toward a uric acid crystalline composition. Elevated urinary pH parameters (pH > 7.5) indicate the presence of urease-producing microbial pathogens, pointing toward a struvite infection stone. Infectious Screening Metrics Active tracking for marked pyuria, positive leukocyte esterase, and bacterial nitrites to rule out an obstructed, infected upper urinary tract system. BMP Immediate quantification of baseline serum creatinine to establish accurate eGFR values. Targeting detection of post-renal AKI from bilateral obstruction, unilateral obstruction in a single functioning kidney, or severe volume depletion. CBC Evaluation for marked leukocytosis. Physiologic Nuance: Mild-to-moderate white blood cell count elevations frequently represent non-specific stress demargination driven by severe pain and repetitive vomiting. High-grade white blood cell shifts demand immediate exclusion of systemic bacteremia or an infected, obstructed urinary system. Adjunctive Lab Pathways Rapid qualitative urine hCG testing. Reflex urine culture execution whenever urinalysis metrics display significant inflammatory profiles or clinical suspicion of UTI is high. 4. IMAGING MODALITIES & ALGORITHMIC CLINICAL SELECTION Non-Contrast CT Diagnostics Gold standard; diagnostic sensitivity and specificity parameters exceed 95% for stones >2 mm. Provides precise quantification of stone diameter (mm), exact localization (proximal, mid, or distal ureter), and degree of secondary hydronephrosis. Excellent structural visualization for detecting or ruling out alternate retroperitoneal, vascular, or intra-abdominal pathologies. Contrast-Enhanced CT Protocols Indicated when alternative intra-abdominal surgical pathology is highly suspected over isolated renal colic. Retains diagnostic capability to identify urinary tract stones >3 mm even within contrast-enhanced phases. NCCT Structural Architecture Limitations Standard stone protocol CT scans are executed in a prone position without IV contrast enhancement. It does not opacify the ureteral lumen. Presents a cumulative radiation exposure penalty when utilized serially across recurrent ED presentations. POCUS / Radiology Ultrasound Direct stone visualization capabilities are modest, operating at approximately 50% to 60% sensitivity, and is highly dependent on anatomical positioning at the extreme proximal ureter or the UVJ. Secondary obstruction tracking: Demonstration of hydronephrosis operates at a high sensitivity of approximately 80%. POCUS Clinical Utility Metrics Eliminates ionizing radiation exposure and allows immediate, rapid real-time execution directly at the patient’s bedside. Confirmation of significant hydronephrosis within a classic clinical presentation yields high post-test probability for stone presence while lowering suspicion for vascular catastrophes like a AAA. KUB Radiography Extremely poor overall diagnostic sensitivity, hovering around 57%. Fails to image radiolucent configurations (pure uric acid matrices) or small stones measuring

One in six teenagers right now has measurable hearing loss, and almost nobody is talking about it. In this conversation with Brandon Sawalich of Starkey Hearing Technologies, we pull back the curtain on what Brandon calls a “quiet pandemic” driven by earbuds, concerts, and a generation blasting sound directly into their cochlea. If you're still pounding music through your earbuds on a daily basis, this episode is your wake-up call. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Connect with Brandon Sawalich Website: https://bit.ly/4mOv98w  Website: https://bit.ly/42ASAc4  Instagram: https://bit.ly/4cPsNlc  Facebook: https://bit.ly/42w3wb3  X: https://bit.ly/41TWYmr  LinkedIn: https://bit.ly/4u6JYFV  Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij  AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD  AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze  BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa  BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV  COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp  CYMBIOTIKA: "ULTIMATE10" FOR 10% OFF: https://bit.ly/4tjyluP  GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk  GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9  GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC  H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg  HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S  PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn  SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V  WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW  Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8foX: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 ​Intro of Show 03:03 Link between Hearing and Brain Health 08:35 Hearing Loss is Irreversible 09:59 Hearing Aids: Technology 13:17 Causes of Hearing Loss and Tinnitus  18:39 Mitigating Tinnitus 20:34 Starkey Hearing Technologies 23:29 How Often Should You Test Your Hearing? 27:04 Risk Factors for Hearing Loss 32:13 Hearing Issues Change One's Personality 32:56 Connect with Brandon and Starkey 35:12 Lancet study: https://bit.ly/4ekLQ8V  35:52 What Does It Mean to You to Be an Ultimate Human? The information provided here is for general informational purposes only and should not be considered as medical or clinical advice. It is not intended to diagnose, treat, cure, or prevent any health condition, and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition or health objectives. The use of any information provided is solely at your own risk, and the provider of this information is not liable for any consequences arising from its use.   Disclosure: Some links to certain products or services are affiliate links, meaning we may earn a commission. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation. Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices